Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 987 articles:
HTML format



Single Articles


    July 2022
  1. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    PubMed     Abstract available


  2. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    PubMed     Abstract available


  3. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    PubMed     Abstract available


  4. SALMANTON-GARCIA J, Stewart FA, Heringer S, Koniordou M, et al
    VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.
    Vaccine. 2022;40:4090-4097.
    PubMed     Abstract available


  5. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    PubMed     Abstract available


  6. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    PubMed     Abstract available


  7. ZHANG Y, Wang Y, Jia C, Li G, et al
    Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects >/=3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00846.
    PubMed     Abstract available


  8. CHADWICK C, Friede M, Moen A, Nannei C, et al
    Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00826.
    PubMed    


  9. HOU Z, Guo J, Lai X, Zhang H, et al
    Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00832.
    PubMed     Abstract available


    June 2022
  10. WONG SC, Chan VW, Lam GKM, Yuen LL, et al
    The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00836.
    PubMed     Abstract available


  11. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    PubMed    


  12. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    PubMed    


  13. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.
    PubMed    


  14. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    PubMed     Abstract available


  15. WILSON B, Mukundan Geetha K
    Nanomedicine to deliver biological macromolecules for treating COVID-19.
    Vaccine. 2022;40:3931-3941.
    PubMed     Abstract available


  16. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    PubMed     Abstract available


  17. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    PubMed     Abstract available


  18. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    PubMed     Abstract available


  19. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    PubMed     Abstract available


  20. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    PubMed     Abstract available


  21. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    PubMed     Abstract available


  22. REICHERZ F, Golding L, Lavoie PM, Abu-Raya B, et al
    Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures.
    Vaccine. 2022;40:3746-3751.
    PubMed     Abstract available


  23. FREW PM, Gonzalez-Casanova I, Otieno NA, Malik FA, et al
    Development of effective messages to promote maternal immunization in Kenya.
    Vaccine. 2022;40:3761-3770.
    PubMed     Abstract available


  24. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    PubMed     Abstract available


  25. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    PubMed     Abstract available


  26. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    PubMed     Abstract available


  27. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    PubMed     Abstract available


  28. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    PubMed     Abstract available


  29. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    PubMed    


  30. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    PubMed    


  31. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    PubMed     Abstract available


  32. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    PubMed     Abstract available


  33. EVANS S, Holt D, Weil-Olivier C, Finnegan G, et al
    Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy.
    Vaccine. 2022;40:3511-3513.
    PubMed    


  34. WILLIAMS E, Craig K, Chiu C, Davies H, et al
    Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
    Vaccine. 2022;40:3484-3489.
    PubMed     Abstract available


  35. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    PubMed     Abstract available


  36. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    PubMed     Abstract available


  37. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    PubMed     Abstract available


  38. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    PubMed     Abstract available


  39. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    PubMed     Abstract available


  40. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    PubMed     Abstract available


  41. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    PubMed     Abstract available


  42. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    PubMed     Abstract available


  43. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    PubMed     Abstract available


  44. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed     Abstract available


  45. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    PubMed     Abstract available


  46. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    PubMed     Abstract available


  47. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    PubMed     Abstract available


  48. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    PubMed     Abstract available


  49. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    PubMed     Abstract available


  50. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    PubMed     Abstract available


  51. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    PubMed     Abstract available


  52. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    PubMed     Abstract available


  53. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    PubMed     Abstract available


    May 2022
  54. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    PubMed     Abstract available


  55. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    PubMed     Abstract available


  56. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    PubMed     Abstract available


  57. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    PubMed     Abstract available


  58. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    PubMed     Abstract available


  59. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    PubMed     Abstract available


  60. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    PubMed     Abstract available


  61. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    PubMed     Abstract available


  62. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    PubMed     Abstract available


  63. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed     Abstract available


  64. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    PubMed     Abstract available


  65. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    PubMed    


  66. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    PubMed     Abstract available


  67. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    PubMed     Abstract available


  68. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    PubMed     Abstract available


  69. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    PubMed     Abstract available


  70. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    PubMed     Abstract available


  71. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    PubMed     Abstract available


  72. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    PubMed     Abstract available


  73. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    PubMed     Abstract available


  74. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    PubMed     Abstract available


  75. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    PubMed     Abstract available


  76. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    PubMed     Abstract available


  77. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    PubMed     Abstract available


  78. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    PubMed     Abstract available


  79. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    PubMed     Abstract available


  80. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    PubMed     Abstract available


  81. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    PubMed     Abstract available


  82. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    PubMed     Abstract available


  83. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    PubMed     Abstract available


  84. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    PubMed     Abstract available


  85. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    PubMed     Abstract available


  86. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    PubMed     Abstract available


  87. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    PubMed     Abstract available


  88. PERUMAL N, Steffen A, Ullrich A, Siedler A, et al
    Impact of COVID-19 immunisation on COVID-19 incidence, hospitalisations, and deaths by age group in Germany from December 2020 to October 2021.
    Vaccine. 2022;40:2910-2914.
    PubMed     Abstract available


  89. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    PubMed     Abstract available


  90. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    PubMed     Abstract available


  91. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    PubMed     Abstract available


  92. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    PubMed     Abstract available


  93. BELLIZZI S, Panu Napodano CM, Pinto S, Pichierri G, et al
    COVID-19 and seasonal influenza: The potential 2021-22 "Twindemic".
    Vaccine. 2022 May 5. pii: S0264-410X(22)00531.
    PubMed    


  94. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    PubMed     Abstract available


  95. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed     Abstract available


  96. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    PubMed     Abstract available


  97. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    PubMed     Abstract available


  98. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    PubMed     Abstract available


  99. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    PubMed     Abstract available


  100. BOSE AS, Rai P, Gupta BP, Pradhan R, et al
    Nepal measles outbreak response immunization during COVID-19: A risk-based intervention strategy.
    Vaccine. 2022;40:2884-2893.
    PubMed     Abstract available


  101. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    PubMed     Abstract available


  102. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed     Abstract available


  103. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    PubMed     Abstract available


    April 2022
  104. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    PubMed     Abstract available


  105. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    PubMed     Abstract available


  106. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    PubMed     Abstract available


  107. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    PubMed     Abstract available


  108. KULCZYCKI A, Shewchuk R
    Back to Basics: A general approach to improving Covid and adult immunization delivery focused on Pharmacy-Based immunization services.
    Vaccine. 2022;40:2647-2649.
    PubMed    


  109. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    PubMed    


  110. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    PubMed    


  111. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    PubMed     Abstract available


  112. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    PubMed     Abstract available


  113. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    PubMed     Abstract available


  114. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    PubMed     Abstract available


  115. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    PubMed     Abstract available


  116. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    PubMed    


  117. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    PubMed     Abstract available


  118. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    PubMed     Abstract available


  119. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    PubMed     Abstract available


  120. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    PubMed     Abstract available


  121. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    PubMed     Abstract available


  122. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    PubMed     Abstract available


  123. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    PubMed     Abstract available


  124. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    PubMed     Abstract available


  125. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    PubMed     Abstract available


  126. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    PubMed     Abstract available


  127. MACINTYRE CR, Heslop DJ, Nguyen P, Adam D, et al
    Pacific Eclipse - A tabletop exercise on smallpox pandemic response.
    Vaccine. 2022;40:2478-2483.
    PubMed     Abstract available


  128. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    PubMed     Abstract available


  129. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    PubMed    


  130. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    PubMed     Abstract available


  131. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    PubMed     Abstract available


  132. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    PubMed     Abstract available


  133. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    PubMed    


  134. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    PubMed     Abstract available


  135. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    PubMed    


  136. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    PubMed     Abstract available


  137. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    PubMed     Abstract available


  138. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    PubMed    


  139. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    PubMed     Abstract available


  140. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    PubMed     Abstract available


  141. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    PubMed     Abstract available


  142. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    PubMed     Abstract available


  143. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    PubMed     Abstract available


  144. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    PubMed    


  145. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    PubMed     Abstract available


  146. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    PubMed     Abstract available


  147. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    PubMed     Abstract available


  148. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    PubMed     Abstract available


  149. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    PubMed     Abstract available


  150. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    PubMed     Abstract available


  151. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    PubMed     Abstract available


    March 2022
  152. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    PubMed     Abstract available


  153. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    PubMed    


  154. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    PubMed     Abstract available


  155. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    PubMed     Abstract available


  156. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    PubMed     Abstract available


  157. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    PubMed     Abstract available


  158. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    PubMed    


  159. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    PubMed    


  160. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    PubMed     Abstract available


  161. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    PubMed     Abstract available


  162. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    PubMed     Abstract available


  163. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    PubMed    


  164. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    PubMed    


  165. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    PubMed     Abstract available


  166. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    PubMed     Abstract available


  167. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    PubMed     Abstract available


  168. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    PubMed     Abstract available


  169. PI-ESTOPINAN F, Perez MT, Fraga A, Bergado G, et al
    A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies.
    Vaccine. 2022;40:1958-1967.
    PubMed     Abstract available


  170. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    PubMed     Abstract available


  171. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    PubMed     Abstract available


  172. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    PubMed     Abstract available


  173. JI C, Piche-Renaud PP, Apajee J, Stephenson E, et al
    Impact of the COVID-19 pandemic on routine immunization coverage in children under 2 years old in Ontario, Canada: A retrospective cohort study.
    Vaccine. 2022;40:1790-1798.
    PubMed     Abstract available


  174. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    PubMed     Abstract available


  175. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    PubMed     Abstract available


  176. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    PubMed     Abstract available


  177. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    PubMed     Abstract available


  178. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    PubMed     Abstract available


  179. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    PubMed     Abstract available


  180. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    PubMed     Abstract available


  181. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    PubMed     Abstract available


  182. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    PubMed     Abstract available


  183. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    PubMed     Abstract available


  184. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    PubMed     Abstract available


  185. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    PubMed     Abstract available


  186. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    PubMed     Abstract available


  187. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    PubMed     Abstract available


  188. LILLVIS DF, Miller CR, Kuo DZ
    Pediatric primary care immunization policies in New York State.
    Vaccine. 2022;40:1458-1463.
    PubMed     Abstract available


  189. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    PubMed     Abstract available


    February 2022
  190. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    PubMed     Abstract available


  191. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    PubMed     Abstract available


  192. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    PubMed     Abstract available


  193. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    PubMed     Abstract available


  194. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    PubMed     Abstract available


  195. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    PubMed     Abstract available


  196. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    PubMed     Abstract available


  197. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    PubMed     Abstract available


  198. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    PubMed     Abstract available


  199. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    PubMed     Abstract available


  200. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    PubMed     Abstract available


  201. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    PubMed     Abstract available


  202. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    PubMed     Abstract available


  203. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    PubMed     Abstract available


  204. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    PubMed     Abstract available


  205. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    PubMed     Abstract available


  206. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    PubMed     Abstract available


  207. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    PubMed     Abstract available


  208. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    PubMed     Abstract available


  209. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    PubMed     Abstract available


  210. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    PubMed     Abstract available


  211. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    PubMed     Abstract available


  212. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    PubMed     Abstract available


  213. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    PubMed     Abstract available


  214. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    PubMed     Abstract available


  215. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    PubMed     Abstract available


  216. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    PubMed     Abstract available


  217. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    PubMed     Abstract available


  218. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    PubMed     Abstract available


  219. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    PubMed     Abstract available


  220. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    PubMed     Abstract available


  221. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    PubMed     Abstract available


  222. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    PubMed     Abstract available


  223. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    PubMed     Abstract available


  224. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    PubMed     Abstract available


  225. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    PubMed     Abstract available


  226. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    PubMed     Abstract available


  227. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    PubMed     Abstract available


  228. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    PubMed     Abstract available


  229. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    PubMed     Abstract available


  230. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    PubMed     Abstract available


  231. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    PubMed     Abstract available


  232. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    PubMed     Abstract available


  233. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    PubMed     Abstract available


  234. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    PubMed     Abstract available


  235. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    PubMed     Abstract available


  236. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    PubMed     Abstract available


  237. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    PubMed     Abstract available


  238. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    PubMed     Abstract available


  239. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    PubMed     Abstract available


  240. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    PubMed     Abstract available


  241. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    PubMed     Abstract available


  242. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    PubMed     Abstract available


  243. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    PubMed     Abstract available


  244. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    PubMed     Abstract available


    January 2022
  245. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    PubMed     Abstract available


  246. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    PubMed     Abstract available


  247. PAGET J, Danielle Iuliano A, Taylor RJ, Simonsen L, et al
    Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01561.
    PubMed     Abstract available


  248. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    PubMed     Abstract available


  249. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    PubMed     Abstract available


  250. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    PubMed     Abstract available


  251. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    PubMed     Abstract available


  252. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    PubMed     Abstract available


  253. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    PubMed     Abstract available


  254. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    PubMed     Abstract available


  255. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    PubMed     Abstract available


  256. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    PubMed     Abstract available


  257. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    PubMed     Abstract available


  258. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    PubMed     Abstract available


  259. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    PubMed     Abstract available


  260. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    PubMed     Abstract available


  261. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    PubMed     Abstract available


  262. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    PubMed     Abstract available


  263. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    PubMed     Abstract available


  264. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    PubMed     Abstract available


  265. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    PubMed     Abstract available


  266. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    PubMed     Abstract available


  267. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    PubMed     Abstract available


  268. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    PubMed     Abstract available


  269. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    PubMed     Abstract available


  270. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    PubMed     Abstract available


  271. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    PubMed     Abstract available


  272. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    PubMed     Abstract available


  273. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    PubMed     Abstract available


  274. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    PubMed     Abstract available


  275. THOMAS S, Durrheim D, Islam F, Higgins H, et al
    Improved childhood immunization coverage using the World Health Organization's Tailoring Immunization Programmes guide (TIP) in a regional centre in Australia.
    Vaccine. 2022;40:18-20.
    PubMed     Abstract available


  276. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    PubMed     Abstract available


    December 2021
  277. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    PubMed     Abstract available


  278. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    PubMed     Abstract available


  279. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    PubMed     Abstract available


  280. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    PubMed     Abstract available


  281. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    PubMed     Abstract available


  282. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    PubMed     Abstract available


  283. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    PubMed     Abstract available


  284. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    PubMed     Abstract available


  285. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    PubMed     Abstract available


  286. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    PubMed     Abstract available


  287. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    PubMed     Abstract available


  288. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    PubMed     Abstract available


  289. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    PubMed     Abstract available


  290. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    PubMed     Abstract available


  291. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    PubMed     Abstract available


  292. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    PubMed     Abstract available


  293. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    PubMed     Abstract available


  294. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    PubMed     Abstract available


  295. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    PubMed     Abstract available


  296. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    PubMed     Abstract available


  297. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    PubMed     Abstract available


  298. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    PubMed     Abstract available


  299. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    PubMed     Abstract available


  300. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    PubMed     Abstract available


  301. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    PubMed     Abstract available


  302. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    PubMed     Abstract available


  303. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    PubMed     Abstract available


  304. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    PubMed     Abstract available


  305. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    PubMed     Abstract available


  306. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    PubMed    


  307. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    PubMed     Abstract available


  308. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    PubMed     Abstract available


  309. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    PubMed     Abstract available


  310. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    PubMed     Abstract available


  311. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    PubMed     Abstract available


  312. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    PubMed     Abstract available


  313. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    PubMed     Abstract available


  314. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    PubMed     Abstract available


  315. HILL R
    COVID-19 from a polio perspective.
    Vaccine. 2021;39:7117-7118.
    PubMed    


  316. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    PubMed     Abstract available


  317. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    PubMed     Abstract available


  318. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    PubMed     Abstract available


  319. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    PubMed     Abstract available


  320. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    PubMed     Abstract available


    November 2021
  321. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    PubMed     Abstract available


  322. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    PubMed    


  323. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    PubMed     Abstract available


  324. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    PubMed     Abstract available


  325. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    PubMed     Abstract available


  326. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    PubMed     Abstract available


  327. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    PubMed     Abstract available


  328. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    PubMed     Abstract available


  329. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    PubMed     Abstract available


  330. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    PubMed     Abstract available


  331. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    PubMed     Abstract available


  332. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    PubMed     Abstract available


  333. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    PubMed     Abstract available


  334. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    PubMed     Abstract available


  335. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    PubMed     Abstract available


  336. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    PubMed     Abstract available


  337. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    PubMed    


  338. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    PubMed     Abstract available


  339. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    PubMed     Abstract available


  340. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    PubMed     Abstract available


  341. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    PubMed     Abstract available


  342. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    PubMed     Abstract available


  343. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    PubMed     Abstract available


  344. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    PubMed     Abstract available


  345. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    PubMed     Abstract available


  346. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    PubMed    


  347. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    PubMed     Abstract available


  348. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    PubMed    


  349. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    PubMed     Abstract available


  350. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    PubMed     Abstract available


  351. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    PubMed     Abstract available


  352. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    PubMed    


  353. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    PubMed     Abstract available


  354. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    PubMed     Abstract available


  355. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    PubMed     Abstract available


  356. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    PubMed     Abstract available


  357. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    PubMed    


  358. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    PubMed    


  359. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    PubMed     Abstract available


    October 2021
  360. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    PubMed     Abstract available


  361. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    PubMed     Abstract available


  362. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    PubMed     Abstract available


  363. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    PubMed     Abstract available


  364. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    PubMed     Abstract available


  365. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    PubMed    


  366. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    PubMed     Abstract available


  367. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    PubMed     Abstract available


  368. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    PubMed     Abstract available


  369. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    PubMed     Abstract available


  370. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    PubMed     Abstract available


  371. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    PubMed     Abstract available


  372. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    PubMed     Abstract available


  373. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    PubMed     Abstract available


  374. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    PubMed     Abstract available


  375. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    PubMed     Abstract available


  376. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    PubMed     Abstract available


  377. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    PubMed     Abstract available


  378. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    PubMed     Abstract available


  379. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    PubMed     Abstract available


  380. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    PubMed     Abstract available


  381. YAMAMOTO N, Takahashi Y, Hayashi S
    Legal and regulatory processes for Japan's COVID-19 immunization program.
    Vaccine. 2021;39:6449-6450.
    PubMed    


  382. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    PubMed     Abstract available


  383. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    PubMed     Abstract available


  384. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    PubMed     Abstract available


  385. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    PubMed    


  386. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    PubMed     Abstract available


  387. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    PubMed     Abstract available


  388. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    PubMed     Abstract available


  389. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    PubMed     Abstract available


  390. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    PubMed    


  391. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    PubMed     Abstract available


  392. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    PubMed     Abstract available


  393. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    PubMed     Abstract available


  394. PALLIKKUTH S, Williams E, Pahwa R, Hoffer M, et al
    Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers.
    Vaccine. 2021;39:6019-6024.
    PubMed     Abstract available


    September 2021
  395. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    PubMed     Abstract available


  396. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    PubMed     Abstract available


  397. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    PubMed     Abstract available


  398. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    PubMed     Abstract available


  399. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    PubMed     Abstract available


  400. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    PubMed    


  401. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    PubMed     Abstract available


  402. LAW JLM, Logan M, Joyce MA, Landi A, et al
    SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
    Vaccine. 2021;39:5769-5779.
    PubMed     Abstract available


  403. LI L, Honda-Okubo Y, Huang Y, Jang H, et al
    Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
    Vaccine. 2021;39:5940-5953.
    PubMed     Abstract available


  404. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    PubMed     Abstract available


  405. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    PubMed     Abstract available


  406. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    PubMed     Abstract available


  407. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01207.
    PubMed     Abstract available


  408. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    PubMed    


  409. RAINA MACINTYRE C, Costantino V, Chanmugam A
    The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01164.
    PubMed     Abstract available


  410. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    PubMed     Abstract available


  411. SELL H, Assi A, Driedger SM, Dube E, et al
    Continuity of routine immunization programs in Canada during the COVID-19 pandemic.
    Vaccine. 2021;39:5532-5537.
    PubMed     Abstract available


  412. SULIMAN S, Pelzer PT, Shaku M, Rozot V, et al
    Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01154.
    PubMed     Abstract available


  413. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    PubMed     Abstract available


  414. VAN HOOSTE WLC
    Influenza vaccination at the workplace.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01188.
    PubMed    


  415. BENJAMIN-CHUNG J, Arnold BF, Mishra K, Kennedy CJ, et al
    City-wide school-located influenza vaccination: A retrospective cohort study.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01161.
    PubMed     Abstract available


  416. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    PubMed     Abstract available


  417. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    PubMed     Abstract available


  418. PERRY M, Akbari A, Cottrell S, Gravenor MB, et al
    Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01198.
    PubMed     Abstract available


  419. JOGI P, Soeorg H, Ingerainen D, Soots M, et al
    Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
    Vaccine. 2021;39:5376-5384.
    PubMed     Abstract available


  420. WAINSTOCK T, Yoles I, Sergienko R, Sheiner E, et al
    Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01191.
    PubMed     Abstract available


  421. MOORE DCBC, Nehab MF, Camacho KG, Reis AT, et al
    Low COVID-19 vaccine hesitancy in Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01192.
    PubMed     Abstract available


  422. EBERHARDT J, Ling J
    Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01189.
    PubMed     Abstract available


  423. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    PubMed     Abstract available


  424. JACOBI CJ, Vaidyanathan B
    Racial differences in anticipated COVID-19 vaccine acceptance among religious populations in the US.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01184.
    PubMed     Abstract available


  425. LEVIN D, Shimon G, Fadlon-Derai M, Gershovitz L, et al
    Myocarditis following COVID-19 vaccination - A case series.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01172.
    PubMed     Abstract available


  426. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    PubMed     Abstract available


  427. ALI A, Dwyer D, Wu Q, Wang Q, et al
    Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01126.
    PubMed     Abstract available


  428. DRUEDAHL LC, Minssen T, Price WN
    Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01163.
    PubMed     Abstract available


  429. BARRY M, Temsah MH, Aljamaan F, Saddik B, et al
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01131.
    PubMed     Abstract available


    August 2021
  430. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    PubMed     Abstract available


  431. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    PubMed     Abstract available


  432. TROGSTAD L, Robertson AH, Mjaaland S, Magnus P, et al
    Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01103.
    PubMed     Abstract available


  433. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    PubMed     Abstract available


  434. DRISCOLL AJ, Ortiz JR, Hartert TV, Riddell CA, et al
    Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory disease.
    Vaccine. 2021;39:5257-5258.
    PubMed    


  435. BROSH-NISSIMOV T, Sorek N, Yeshayahu M, Zherebovich I, et al
    Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01148.
    PubMed     Abstract available


  436. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    PubMed     Abstract available


  437. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    PubMed     Abstract available


  438. HARPAZ R
    COVID-19 vaccine safety monitoring: Might differential healthcare seeking introduce detection bias into rates of medical events and cause false safety signals?
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)00712.
    PubMed    


  439. ROTENBERG S, Downer MB, Cooper J
    Making COVID-19 vaccinations accessible for people with disabilities.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01110.
    PubMed    


  440. PIERCE-RUIZ C, Santana WI, Sutton WJH, Fischler DA, et al
    Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry.
    Vaccine. 2021;39:5106-5115.
    PubMed     Abstract available


  441. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    PubMed     Abstract available


  442. BRAEYE T, Cornelissen L, Catteau L, Haarhuis F, et al
    Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01108.
    PubMed     Abstract available


  443. DUDLEY MZ, Bernier R, Brewer J, Salmon DA, et al
    Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01070.
    PubMed     Abstract available


  444. PENG HK, Dombkowski KJ, Freed GL, Creary SE, et al
    Influenza immunization coverage of children with sickle cell disease.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01072.
    PubMed     Abstract available


  445. LIU S, Liu J
    Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01106.
    PubMed     Abstract available


  446. LAUFER RS, Driscoll AJ, Baral R, Buchwald AG, et al
    Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Vaccine. 2021;39:5037-5045.
    PubMed     Abstract available


  447. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    PubMed     Abstract available


  448. LAIGLE V, Postma MJ, Pavlovic M, Cadeddu C, et al
    Vaccine market access pathways in the EU27 and the United Kingdom-analysis and recommendations for improvements.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)00918.
    PubMed     Abstract available


  449. CIAPPONI A, Bardach A, Mazzoni A, Alconada T, et al
    Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01067.
    PubMed     Abstract available


  450. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    PubMed     Abstract available


  451. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    PubMed     Abstract available


  452. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    PubMed     Abstract available


  453. KANJI JN, Bailey A, Fenton J, Ling SH, et al
    Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01042.
    PubMed     Abstract available


  454. OKAMURA S, Ebina H
    Could live attenuated vaccines better control COVID-19?
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01038.
    PubMed     Abstract available


  455. RIZK JG, Barr CE, Rizk Y, Lewin JC, et al
    The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action.
    Vaccine. 2021 Aug 10. pii: S0264-410X(21)01006.
    PubMed    


  456. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    PubMed     Abstract available


  457. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    PubMed     Abstract available


  458. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    PubMed     Abstract available


  459. PHILLIPS A, Carlson S, Danchin M, Beard F, et al
    From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00950.
    PubMed     Abstract available


  460. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    PubMed     Abstract available


  461. TAYLOR SC, Hurst B, Martiszus I, Hausman MS, et al
    Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)01013.
    PubMed     Abstract available


  462. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    PubMed     Abstract available


  463. FRIEDENSOHN L, Zur M, Timofeyev M, Burshtein S, et al
    Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01010.
    PubMed     Abstract available


  464. DODD RH, Pickles K, Cvejic E, Cornell S, et al
    Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01008.
    PubMed     Abstract available


  465. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    PubMed     Abstract available


  466. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    PubMed     Abstract available


  467. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    PubMed     Abstract available


    July 2021
  468. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    PubMed     Abstract available


  469. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    PubMed     Abstract available


  470. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    PubMed    


  471. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    PubMed     Abstract available


  472. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    PubMed     Abstract available


  473. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    PubMed    


  474. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    PubMed     Abstract available


  475. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    PubMed     Abstract available


  476. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    PubMed    


  477. MICHOS A, Tatsi EB, Filippatos F, Dellis C, et al
    Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00960.
    PubMed     Abstract available


  478. CALLAHAN AG, Coleman-Cowger VH, Schulkin J, Power ML, et al
    Racial disparities in influenza immunization during pregnancy in the United States: A narrative review of the evidence for disparities and potential interventions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00905.
    PubMed     Abstract available


  479. BURKE PF, Masters D, Massey G
    Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00947.
    PubMed     Abstract available


  480. TEASDALE CA, Borrell LN, Shen Y, Kimball S, et al
    Parental plans to vaccinate children for COVID-19 in New York city.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00949.
    PubMed     Abstract available


  481. SUNDARAM M, Nasreen S, Calzavara A, He S, et al
    Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00951.
    PubMed     Abstract available


  482. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    PubMed     Abstract available


  483. ARIAS-FERNANDEZ L, San-Roman Montero J, Gil-Prieto R, Walter S, et al
    Burden of pneumonia in patients with viral and bacterial coinfection in Spain during six consecutive influenza seasons, from 2009-10 to 2014-15.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00912.
    PubMed     Abstract available


  484. HERVE PL, Dhelft V, Zuniga A, Ghasparian A, et al
    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Vaccine. 2021;39:4555-4563.
    PubMed     Abstract available


  485. MATHIVATHANAN K
    Will COVID-19 vaccine equity be possible in India?
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00927.
    PubMed    


  486. TISSOT N, Brunel AS, Bozon F, Rosolen B, et al
    Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00925.
    PubMed     Abstract available


  487. CHUA H, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00873.
    PubMed     Abstract available


  488. INGROLE RSJ, Tao W, Joshi G, Gill HS, et al
    M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00909.
    PubMed     Abstract available


  489. PAUL E, Brown GW, Kalk A, Ridde V, et al
    Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00923.
    PubMed    


  490. HANLY M, Churches T, Fitzgerald O, MacIntyre CR, et al
    Vaccinating Australia: How long will it take?
    Vaccine. 2021 Jul 17. pii: S0264-410X(21)00865.
    PubMed     Abstract available


  491. FLUCKIGER AC, Ontsouka B, Bozic J, Diress A, et al
    An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00911.
    PubMed     Abstract available


  492. INSERRA F, Tajer C, Antonietti L, Mariani J, et al
    Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00908.
    PubMed    


  493. JAIN R, Chopra A, Falezan C, Patel M, et al
    COVID-19 related immunization disruptions in Rajasthan, India: A retrospective observational study.
    Vaccine. 2021;39:4343-4350.
    PubMed     Abstract available


  494. PICHE-RENAUD PP, Ji C, Farrar DS, Friedman JN, et al
    Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada.
    Vaccine. 2021;39:4373-4382.
    PubMed     Abstract available


  495. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    PubMed     Abstract available


  496. HAYMAN B, Suri R, Prasad SD
    COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00866.
    PubMed     Abstract available


  497. LAZAROS G, Klein AL, Hatziantoniou S, Tsioufis C, et al
    The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00875.
    PubMed    


  498. CLARKE M, Goodchild LM, Evans S, Giles LC, et al
    Body mass index and vaccine responses following influenza vaccination during pregnancy.
    Vaccine. 2021 Jul 12. pii: S0264-410X(21)00826.
    PubMed     Abstract available


  499. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    PubMed     Abstract available


  500. MATEO-URDIALES A, Del Manso M, Andrianou X, Spuri M, et al
    Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00862.
    PubMed     Abstract available


  501. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    PubMed     Abstract available


  502. LO CY, Misplon JA, Li X, Price GE, et al
    Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00833.
    PubMed     Abstract available


  503. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    PubMed     Abstract available


    June 2021
  504. HINES AM, Murphy N, Mullin C, Barillas J, et al
    Henoch-Schonlein purpura presenting post COVID-19 vaccination.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00841.
    PubMed    


  505. YOUSSEF Y, Chmaisse A, Boutros C, Chamseddine S, et al
    The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review.
    Vaccine. 2021;39:3803-3813.
    PubMed     Abstract available


  506. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    PubMed    


  507. BANKS C, Portnoy A, Moi F, Boonstoppel L, et al
    Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00838.
    PubMed     Abstract available


  508. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    PubMed     Abstract available


  509. MYLES IA, Vinciguerra JS, Premus RT
    Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00811.
    PubMed     Abstract available


  510. GUAN L, Yu Y, Wu X, Nie J, et al
    The first Chinese national standards for SARS-CoV-2 neutralizing antibody.
    Vaccine. 2021;39:3724-3730.
    PubMed     Abstract available


  511. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    PubMed     Abstract available


  512. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    PubMed     Abstract available


  513. GOOCH KE, Smith TRF, Salguero FJ, Fotheringham SA, et al
    One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00807.
    PubMed     Abstract available


  514. TRENT M, Seale H, Chughtai AA, Salmon D, et al
    Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00798.
    PubMed     Abstract available


  515. CHEN IH, Ahorsu DK, Ko NY, Yen CF, et al
    Adapting the Motors of Influenza Vaccination Acceptance Scale into the Motors of COVID-19 Vaccination Acceptance Scale: Psychometric evaluation among mainland Chinese university students.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00794.
    PubMed     Abstract available


  516. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    PubMed     Abstract available


  517. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    PubMed     Abstract available


  518. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    PubMed     Abstract available


  519. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    PubMed     Abstract available


  520. BIFULCO M, Pisanti S, Fusco I
    Lessons from the 1656 Neapolitan Plague: Something to learn for the current coronavirus Pandemic?
    Vaccine. 2021;39:3641-3643.
    PubMed     Abstract available


  521. JETHWA H, Wong R, Abraham S
    Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
    Vaccine. 2021;39:3541-3543.
    PubMed    


  522. PRASAD N, Read JM, Jewell C, Waite B, et al
    Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00708.
    PubMed     Abstract available


  523. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    PubMed     Abstract available


  524. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    PubMed    


  525. IVANOV V, Oomens AGP, Papin JF, Staats R, et al
    Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00737.
    PubMed     Abstract available


  526. FERRARI D, Di Resta C, Tomaiuolo R, Sabetta E, et al
    Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00756.
    PubMed     Abstract available


  527. LIPSITCH M, Kahn R
    Interpreting vaccine efficacy trial results for infection and transmission.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00735.
    PubMed     Abstract available


  528. MCFADDEN K, Heywood A, Dyda A, Kaufman J, et al
    Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
    Vaccine. 2021;39:3467-3472.
    PubMed     Abstract available


  529. BEAU RENEER Z, Abreu RB, Jamal US, Corn MR, et al
    Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00659.
    PubMed     Abstract available


  530. HSIA J, Zhao G, Lu PJ, Town M, et al
    Estimating bias from internet non-use for a hybrid web vaccination survey - 2013-2017 Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00675.
    PubMed     Abstract available


  531. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    PubMed     Abstract available


  532. LUTZ CS, Biggerstaff M, Rolfes MA, Lafond KE, et al
    Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00557.
    PubMed     Abstract available


  533. GUNTUKU SC, Buttenheim AM, Sherman G, Merchant RM, et al
    Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00738.
    PubMed     Abstract available


  534. IKILEZI G, Bachmeier SD, Cogswell IE, Maddison ER, et al
    Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data.
    Vaccine. 2021;39:3410-3418.
    PubMed     Abstract available


  535. NUZHATH T, Ajayi KV, Fan Q, Hotez P, et al
    Childhood immunization during the COVID-19 pandemic in Texas.
    Vaccine. 2021;39:3333-3337.
    PubMed     Abstract available


  536. SILVEIRA MF, Tonial CT, Goretti K Maranhao A, Teixeira AMS, et al
    Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey.
    Vaccine. 2021;39:3404-3409.
    PubMed     Abstract available


  537. JENSEN A, A F Simoes E, Bohn Christiansen C, Graff Stensballe L, et al
    Respiratory syncytial virus and influenza hospitalizations in Danish children 2010-2016.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00705.
    PubMed     Abstract available


  538. HOEHL S, Ciesek S, Graf J, Wicker S, et al
    A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00736.
    PubMed    


  539. ANDAYI F, Emukule GO, Osoro E, Ndegwa LK, et al
    Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemic.
    Vaccine. 2021 Jun 7. pii: S0264-410X(21)00643.
    PubMed     Abstract available


  540. RAZ A, Keshet Y, Popper-Giveon A, Karkabi MS, et al
    One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.
    Vaccine. 2021 Jun 5. pii: S0264-410X(21)00714.
    PubMed    


  541. DAL-RE R, Launay O
    Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00703.
    PubMed    


  542. STUURMAN AL, Biccler J, Carmona A, Descamps A, et al
    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00654.
    PubMed     Abstract available


  543. GATES A, Rahman S, Sim S, Pillay J, et al
    Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00640.
    PubMed     Abstract available


  544. FERDINANDS JM, Thompson MG, Blanton L, Spencer S, et al
    Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00562.
    PubMed     Abstract available


  545. SHINGAI M, Nomura N, Sekiya T, Ohno M, et al
    Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00660.
    PubMed     Abstract available


  546. LASKY T, McMahon AW, Hua W, Forshee R, et al
    Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00666.
    PubMed     Abstract available


  547. WANG Y, Zhang Y, Wu H, Huang L, et al
    Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00665.
    PubMed     Abstract available


  548. DEY A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, et al
    Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00706.
    PubMed     Abstract available


  549. PATEL MK, Bergeri I, Bresee JS, Cowling BJ, et al
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00707.
    PubMed     Abstract available


    May 2021
  550. ZIPFEL CM, Colizza V, Bansal S
    The missing season: The impacts of the COVID-19 pandemic on influenza.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00635.
    PubMed     Abstract available


  551. LEWIS NS, Banyard AC, Essen S, Whittard E, et al
    Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 influenza A viruses and impact on vaccine use for mitigation and control.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00655.
    PubMed     Abstract available


  552. BARDENHEIER BH, Gravenstein S, Blackman C, Gutman R, et al
    Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00683.
    PubMed     Abstract available


  553. ABU MOUCH S, Roguin A, Hellou E, Ishai A, et al
    Myocarditis following COVID-19 mRNA vaccination.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00682.
    PubMed     Abstract available


  554. GURWITZ D
    COVID-19 vaccine hesitancy: Lessons from Israel.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00680.
    PubMed    


  555. KESSELS R, Luyten J, Tubeuf S
    Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00664.
    PubMed     Abstract available


  556. VANHEMS P
    A breath of humanity in the era of Covid-19 vaccine.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00638.
    PubMed    


  557. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    PubMed     Abstract available


  558. SAM IC, Ahmad Jaafar N, Wong LP, Nathan AM, et al
    Socioeconomic costs of children <5 years hospitalised with acute respiratory infections in Kuala Lumpur, Malaysia.
    Vaccine. 2021;39:2983-2988.
    PubMed     Abstract available


  559. VOGEL TP, Top KA, Karatzios C, Hilmers DC, et al
    Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3037-3049.
    PubMed     Abstract available


  560. SERAZIN NA, Edem B, Williams SR, Ortiz JR, et al
    Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3028-3036.
    PubMed     Abstract available


  561. AIZAWA Y, Katsuta T, Sakiyama H, Tanaka-Taya K, et al
    Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00636.
    PubMed     Abstract available


  562. NICHOLLS LAB, Gallant AJ, Cogan N, Rasmussen S, et al
    Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00544.
    PubMed     Abstract available


  563. KIM S, Williams TC, Viboud C, Campbell H, et al
    RSV genomic diversity and the development of a globally effective RSV intervention.
    Vaccine. 2021;39:2811-2820.
    PubMed     Abstract available


  564. NAG K, Chandra Baray J, Rahman Khan M, Mahmud A, et al
    An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00607.
    PubMed     Abstract available


  565. LUK TT, Zhao S, Wu Y, Wong JY, et al
    Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00608.
    PubMed     Abstract available


  566. CHAN YW, Wong ML, Kwok FY, Au AK, et al
    The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00541.
    PubMed     Abstract available


  567. GUBERNOT D, Jazwa A, Niu M, Baumblatt J, et al
    U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00578.
    PubMed     Abstract available


  568. WOOD RM, Murch BJ, Moss SJ, Tyler JMB, et al
    Operational research for the safe and effective design of COVID-19 mass vaccination centres.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00588.
    PubMed    


  569. CHUNG JR, Flannery B, Kim SS, Gaglani M, et al
    Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00555.
    PubMed     Abstract available


  570. KIM TH, Choi JH, Park SH, Yoo JH, et al
    Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged >/= 65 years.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00551.
    PubMed     Abstract available


  571. KRAIGSLEY AM, Moore KA, Bolster A, Peters M, et al
    Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00502.
    PubMed     Abstract available


  572. AFIFI TO, Salmon S, Taillieu T, Stewart-Tufescu A, et al
    Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00590.
    PubMed     Abstract available


  573. LONGCHAMPS C, Ducarroz S, Crouzet L, Vignier N, et al
    COVID-19 vaccine hesitancy among persons living in homeless shelters in France.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00563.
    PubMed     Abstract available


  574. LEUNG VKY, Fox A, Carolan LA, Aban M, et al
    Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00483.
    PubMed     Abstract available


  575. POWELL H, Liu H, Pekosz A
    Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00535.
    PubMed     Abstract available


  576. PASTORINO R, Villani L, La Milia DI, Ieraci R, et al
    Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00566.
    PubMed     Abstract available


  577. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    PubMed     Abstract available


  578. CORREIA R, Meneses L, Richheimer C, Alves PM, et al
    Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00480.
    PubMed     Abstract available


  579. SOMIYA M, Mine S, Yasukawa K, Ikeda S, et al
    Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00548.
    PubMed    


    April 2021
  580. EYAL N, Gerhard T, Strom BL
    Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00526.
    PubMed    


  581. WELSH KJ, Baumblatt J, Chege W, Goud R, et al
    Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00524.
    PubMed     Abstract available


  582. KINI A, Morgan R, Kuo H, Shea P, et al
    Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00448.
    PubMed     Abstract available


  583. SAITOH A, Okabe N
    Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00460.
    PubMed     Abstract available


  584. KWON JH, Criado MF, Killmaster L, Ali MZ, et al
    Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh.
    Vaccine. 2021 Apr 25. pii: S0264-410X(21)00459.
    PubMed     Abstract available


  585. KREPS SE, Kriner DL
    Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00503.
    PubMed     Abstract available


  586. MACINTYRE CR, Costantino V, Trent M
    Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00501.
    PubMed     Abstract available


  587. OLATUNJI EA, Ogunsola AS, Khodakarami N, Callaghan T, et al
    Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00451.
    PubMed     Abstract available


  588. DADARI I, Higgins-Steele A, Sharkey A, Charlet D, et al
    Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
    Vaccine. 2021;39:2434-2444.
    PubMed     Abstract available


  589. WANG C, Han B, Zhao T, Liu H, et al
    Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00455.
    PubMed     Abstract available


  590. LEVIN Y, Balakirski NM, Caraco Y, Ben-Ami E, et al
    Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00452.
    PubMed    


  591. HAMILTON RA, Krockow EM, Vekria P
    Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00407.
    PubMed     Abstract available


  592. PU J, Yu Q, Yin Z, Zhang Y, et al
    The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00431.
    PubMed     Abstract available


  593. POLUEKTOV Y, George M, Daftarian P, Delcommenne MC, et al
    Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Vaccine. 2021;39:2110-2116.
    PubMed     Abstract available


  594. HOGAN AB, Winskill P, Watson OJ, Walker PGT, et al
    Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00427.
    PubMed     Abstract available


  595. PAGLIUSI S, Hayman B, Jarrett S
    Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Vaccine. 2021 Apr 7. pii: S0264-410X(21)00293.
    PubMed     Abstract available


  596. DANIELS V, Saxena K, Roberts C, Kothari S, et al
    Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00428.
    PubMed     Abstract available


  597. GRAMACHO WG, Turgeon M
    When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00396.
    PubMed     Abstract available


  598. HATZIANTONIOU S, Maltezou HC, Tsakris A, Poland GA, et al
    Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00377.
    PubMed    


    March 2021
  599. PELTON SI, Divino V, Postma MJ, Shah D, et al
    A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00347.
    PubMed     Abstract available


  600. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    PubMed     Abstract available


  601. KUTER BJ, Offit PA, Poland GA
    The development of COVID-19 vaccines in the United States: Why and how so fast?
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00383.
    PubMed    


  602. RUSSO AG, Decarli A, Valsecchi MG
    Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00382.
    PubMed     Abstract available


  603. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    PubMed     Abstract available


  604. SALMON DA, Dudley MZ, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00315.
    PubMed     Abstract available


  605. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    PubMed     Abstract available


  606. HAEDER SF
    Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00348.
    PubMed     Abstract available


  607. KOCHHAR S, Dube E, Graham J, Jee Y, et al
    COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00364.
    PubMed    


  608. ZHANG Y, Li D, Zhao H, Wang L, et al
    The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00371.
    PubMed    


  609. ANTONELLI INCALZI R, Trevisan C, Del Signore S, Volpato S, et al
    Are vaccines against COVID-19 tailored to the most vulnerable people?
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00370.
    PubMed    


  610. ANGELIS A, Darrow J
    Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00346.
    PubMed    


  611. KENDAL A
    Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00283.
    PubMed    


  612. CHEN D, Ye Z, Pi Z, Mizukami S, et al
    Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00324.
    PubMed     Abstract available


  613. VILCHES TN, Zhang K, Van Exan R, Langley JM, et al
    Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00362.
    PubMed     Abstract available


  614. CAMBOU MC, Copeland TP, Nielsen-Saines K, Macinko J, et al
    Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00294.
    PubMed     Abstract available


  615. GRAUPENSPERGER S PHD, Abdallah DA, Lee CM
    Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00286.
    PubMed     Abstract available


  616. SZIGETI R, Kellermayer R
    Natural unblinding of BCG vaccination trials.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00320.
    PubMed     Abstract available


  617. ALLINGTON D, McAndrew S, Moxham-Hall VL, Duffy B, et al
    Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00234.
    PubMed     Abstract available


  618. CHOI UY, Kim KH, Lee KY, Kim JH, et al
    Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00273.
    PubMed     Abstract available


  619. NET P, Colrat F, Nascimento Costa M, Bianic F, et al
    Estimating public health and economic benefits along 10 years of Fluzone(R) High Dose in the United States.
    Vaccine. 2021;39 Suppl 1:A56-A69.
    PubMed     Abstract available


  620. BUTTERY JP
    Developing standard safety outcomes for COVID-19 vaccines.
    Vaccine. 2021 Mar 12. pii: S0264-410X(21)00272.
    PubMed    


  621. LEE J, Li Y, Li Y, Cino-Ozuna AG, et al
    Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00268.
    PubMed     Abstract available


  622. BERTRAN K, Kassa A, Criado MF, Nunez IA, et al
    Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00266.
    PubMed     Abstract available


  623. EBAMA MS, Chu SY, Azziz-Baumgartner E, Lafond KE, et al
    Ancillary benefits of seasonal influenza vaccination in middle-income countries.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00228.
    PubMed     Abstract available


  624. LATKIN C, Dayton LA, Yi G, Konstantopoulos A, et al
    COVID-19 vaccine intentions in the United States, a social-ecological framework.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00238.
    PubMed     Abstract available


  625. REPERANT LA, Osterhaus ADME
    COVID-19 vaccination and critical care capacity: Perilous months ahead.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00316.
    PubMed    


  626. WENTZELL E, Racila AM
    The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00317.
    PubMed     Abstract available


  627. GUIDRY JPD, Perrin PB, Laestadius LI, Vraga EK, et al
    U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00306.
    PubMed     Abstract available


  628. SADARANGANI M, Abu Raya B, Conway JM, Iyaniwura SA, et al
    Importance of COVID-19 vaccine efficacy in older age groups.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00288.
    PubMed     Abstract available


  629. KISZEWSKI AE, Cleary EG, Jackson MJ, Ledley FD, et al
    NIH funding for vaccine readiness before the COVID-19 pandemic.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00290.
    PubMed     Abstract available


  630. PULLAN S, Dey M
    Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00287.
    PubMed     Abstract available


  631. BLACK SB, Law B, Chen RT, Dekker CL, et al
    The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00284.
    PubMed     Abstract available


  632. GASPAR EB, De Gaspari E
    Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
    Vaccine. 2021;39:1473-1475.
    PubMed    


  633. YOKOMICHI H, Kojima R, Horiuchi S, Ooka T, et al
    Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00224.
    PubMed     Abstract available


  634. DU Y, Xu Y, Feng J, Hu L, et al
    Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00274.
    PubMed     Abstract available


  635. KUO H, Shapiro JR, Dhakal S, Morgan R, et al
    Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00227.
    PubMed     Abstract available


  636. WOO EJ, Moro PL
    Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00232.
    PubMed     Abstract available


  637. STURM L, Kasting ML, Head KJ, Hartsock JA, et al
    Influenza vaccination in the time of COVID-19: A national U.S. survey of adults.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00271.
    PubMed     Abstract available


  638. HELMKAMP LJ, Szilagyi PG, Zimet G, Saville AW, et al
    A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00206.
    PubMed     Abstract available


  639. FELL DB, Dimitris MC, Hutcheon JA, Ortiz JR, et al
    Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00261.
    PubMed     Abstract available


    February 2021
  640. WANG J, Lyu Y, Zhang H, Jing R, et al
    Willingness to pay and financing preferences for COVID-19 vaccination in China.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00240.
    PubMed     Abstract available


  641. SHEN M, Zu J, Fairley CK, Pagan JA, et al
    Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00236.
    PubMed     Abstract available


  642. SANDBRINK JB, Koblentz GD
    Biosecurity risks associated with vaccine platform technologies.
    Vaccine. 2021 Feb 25. pii: S0264-410X(21)00171.
    PubMed     Abstract available


  643. SELL TK, Gastfriend D, Watson M, Watson C, et al
    Building the global vaccine manufacturing capacity needed to respond to pandemics.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00165.
    PubMed    


  644. MUNOZ FM, Cramer JP, Dekker CL, Dudley MZ, et al
    Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00094.
    PubMed     Abstract available


  645. VERELST F, Beutels P, Hens N, Willem L, et al
    Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
    Vaccine. 2021 Feb 22. pii: S0264-410X(21)00168.
    PubMed     Abstract available


  646. SU QD, Zou YN, Yi Y, Shen LP, et al
    Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Vaccine. 2021;39:1241-1247.
    PubMed     Abstract available


  647. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.
    Vaccine. 2021;39:1248-1256.
    PubMed     Abstract available


  648. ELSENPETER HMS
    How COVID exposed the hypocrisy within me.
    Vaccine. 2021;39:1178-1179.
    PubMed    


  649. ORTIZ JR, Robertson J, Hsu JS, Yu SL, et al
    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00204.
    PubMed     Abstract available


  650. CHANG LJ, Anderson EJ, Jeanfreau R, He Y, et al
    Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6months through<18years of age: A randomized controlled phase II dose-finding trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00162.
    PubMed     Abstract available


  651. KUTER BJ, Browne S, Momplaisir FM, Feemster KA, et al
    Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia.
    Vaccine. 2021 Feb 16. pii: S0264-410X(21)00185.
    PubMed     Abstract available


  652. WU MJ, Chung JR, Kim SS, Jackson ML, et al
    Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00106.
    PubMed     Abstract available


  653. GURWITZ D
    Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries.
    Vaccine. 2021;39:1027.
    PubMed    


  654. RID A, Shah SK, Miller FG, Danis M, et al
    Ethical trade-offs in vaccine development and distribution-Response to Gurwitz.
    Vaccine. 2021;39:1028-1029.
    PubMed    


  655. WARD BJ, Seguin A, Couillard J, Trepanier S, et al
    Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00004.
    PubMed     Abstract available


  656. POLAND CM, Matthews AKS, Poland GA
    Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00154.
    PubMed    


  657. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Corrigendum to "Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance" [Vaccine 38(43) (2020) 6757-6765].
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00105.
    PubMed    


  658. CHU L, McPhee R, Huang W, Bennett H, et al
    A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00153.
    PubMed     Abstract available


  659. ROBINSON E, Jones A, Lesser I, Daly M, et al
    International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.
    Vaccine. 2021 Feb 6. pii: S0264-410X(21)00140.
    PubMed     Abstract available


  660. KUMAR N, Bhartiya S, Singh T
    Duration of anti-SARS-CoV-2 antibodies much shorter in India.
    Vaccine. 2021;39:886-888.
    PubMed     Abstract available


  661. DIACO M, Chang LJ, Seet B, Robertson CA, et al
    Introductory paper: High dose influenza vaccine.
    Vaccine. 2021 Feb 3. pii: S0264-410X(20)31147.
    PubMed     Abstract available


  662. WILCK MB, Jin Xu Z, Stek JE, Goveia MG, et al
    Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS).
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00073.
    PubMed     Abstract available


    January 2021
  663. AXELSEN PH, Poland GA
    Vaccines, masks, distancing and credibility: An urgent warning for pandemic management.
    Vaccine. 2021 Jan 31. pii: S0264-410X(21)00079.
    PubMed    


  664. COLRAT F, Thommes E, Largeron N, Alvarez FP, et al
    Economic evaluation of high-dose inactivated influenza vaccine in adults aged >/=65 years: A systematic literature review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(20)31603.
    PubMed     Abstract available


  665. HAMPTON LM, Aggarwal R, Evans SJW, Law B, et al
    General determination of causation between Covid-19 vaccines and possible adverse events.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00096.
    PubMed    


  666. BERMAN L, Riedel M
    Coping with COVID.
    Vaccine. 2021;39:777-778.
    PubMed    


  667. KIM SH, Paldurai A, Xiao S, Collins PL, et al
    Retraction notice to "Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens" [Vaccine 32(35) (2014) 4428-4435].
    Vaccine. 2021;39:775.
    PubMed    


  668. WANG Y, Chen L, Cheng F, Biggerstaff M, et al
    Economic burden of influenza illness among children under 5 years in Suzhou, China: Report from the cost surveys during 2011/12 to 2016/17 influenza seasons.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31672.
    PubMed     Abstract available


  669. OKOLI GN, Racovitan F, Abdulwahid T, Righolt CH, et al
    Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studie
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00048.
    PubMed     Abstract available


  670. BHUIYAN MU, Stiboy E, Hassan MZ, Chan M, et al
    Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis.
    Vaccine. 2021;39:667-677.
    PubMed     Abstract available


  671. JAMROZIK E, Littler K, Bull S, Emerson C, et al
    Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Vaccine. 2021;39:633-640.
    PubMed     Abstract available


  672. BALASUBRAMANI GK, Zimmerman RK, Eng H, Lyons J, et al
    Comparison of local influenza vaccine effectiveness using two methods.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00017.
    PubMed     Abstract available


  673. DAL-RE R
    US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00077.
    PubMed    


  674. POLAND EG, McGuire DK, Ratishvili T, Poland GA, et al
    The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31694.
    PubMed    


  675. WINOKUR P, El Sahly HM, Mulligan MJ, Frey SE, et al
    Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31504.
    PubMed     Abstract available


  676. CAO L, Lou J, Zhao S, Chan RWY, et al
    In silico prediction of influenza vaccine effectiveness by sequence analysis.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00006.
    PubMed     Abstract available


  677. REEMERS S, Verstegen I, Basten S, Hubers W, et al
    A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00022.
    PubMed     Abstract available


  678. FATOBA AJ, Maharaj L, Adeleke VT, Okpeku M, et al
    Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00003.
    PubMed     Abstract available


  679. SCOTT EM, Stein R, Brown MF, Hershberger J, et al
    Vaccination patterns of the northeast Ohio Amish revisited.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00026.
    PubMed     Abstract available


  680. WHITAKER JA, Parikh SA, Shanafelt TD, Kay NE, et al
    The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Vaccine. 2021 Jan 15. pii: S0264-410X(21)00001.
    PubMed     Abstract available


  681. GUALANO MR, Corradi A, Voglino G, Catozzi D, et al
    Healthcare Workers' (HCWs) attitudes towards mandatory influenza vaccination: A systematic review and meta-analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31655.
    PubMed     Abstract available


  682. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    PubMed     Abstract available


  683. BURGER AE, Reither EN, Mamelund SE, Lim S, et al
    Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31666.
    PubMed     Abstract available


  684. WIEMKEN TL, Rutschman AS
    Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00018.
    PubMed    


  685. SINGH J, Malik D, Raina A
    Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00015.
    PubMed     Abstract available


  686. RUIZ JB, Bell RA
    Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00014.
    PubMed     Abstract available


  687. BEIGI RH, Krubiner C, Jamieson DJ, Lyerly AD, et al
    The need for inclusion of pregnant women in COVID-19 vaccine trials.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31671.
    PubMed    


  688. GOLD MS, Lincoln G, Cashman P, Braunack-Mayer A, et al
    Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Vaccine. 2021;39:332-342.
    PubMed     Abstract available


  689. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    PubMed     Abstract available


  690. WILLIAMS J, Degeling C, McVernon J, Dawson A, et al
    How should we conduct pandemic vaccination?
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31639.
    PubMed     Abstract available


  691. KELSO JM
    Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31696.
    PubMed    


  692. KOHLI M, Maschio M, Becker D, Weinstein MC, et al
    The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31690.
    PubMed     Abstract available


  693. MIDDELDORP M, van Lier A, van der Maas N, Veldhuijzen I, et al
    Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31692.
    PubMed     Abstract available


  694. WONG MCS, Wong ELY, Huang J, Cheung AWL, et al
    Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31695.
    PubMed     Abstract available


  695. SU JR, McNeil MM, Welsh KJ, Marquez PL, et al
    Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31614.
    PubMed     Abstract available


  696. GODINOT LD, Sicsic J, Lachatre M, Bouvet E, et al
    Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Vaccine. 2021 Jan 5. pii: S0264-410X(20)31637.
    PubMed     Abstract available


    December 2020
  697. JIANG X, Shang X, Lin J, Zhao Y, et al
    Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31608.
    PubMed     Abstract available


  698. DAMJANOVSKA S, Smith C, Sayin I, Burant CJ, et al
    Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31631.
    PubMed     Abstract available


  699. ZHONG Y, Clapham HE, Aishworiya R, Chua YX, et al
    Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Vaccine. 2020 Dec 26. pii: S0264-410X(20)31634.
    PubMed     Abstract available


  700. MORO PL, Marquez P
    Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31613.
    PubMed     Abstract available


  701. THANGARAJAH D, Malo JA, Field E, Andrews R, et al
    Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31579.
    PubMed     Abstract available


  702. MCFADDEN K, Seale H
    A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31610.
    PubMed     Abstract available


  703. SCHMIT T, Kuntz M, Patel D, Nadeem Khan M, et al
    Anti-capsular immunity to Streptococcus pneumoniae serotype 22F prevents bacterial transmission in murine colonization and influenza virus co-infection models.
    Vaccine. 2020 Dec 18. pii: S0264-410X(20)31558.
    PubMed     Abstract available


  704. SPARROW E, Wood JG, Chadwick C, Newall AT, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2019.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31585.
    PubMed     Abstract available


  705. FULVINI AA, Tuteja A, Le J, Pokorny BA, et al
    HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31563.
    PubMed     Abstract available


  706. BORRIELLO A, Master D, Pellegrini A, Rose JM, et al
    Preferences for a COVID-19 vaccine in Australia.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31599.
    PubMed     Abstract available


  707. BOKEMPER SE, Huber GA, Gerber AS, James EK, et al
    Timing of COVID-19 vaccine approval and endorsement by public figures.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31616.
    PubMed     Abstract available


  708. SANFTENBERG L, Kuehne F, Anraad C, Jung-Sievers C, et al
    Assessing the impact of shared decision making processes on influenza vaccination rates in adult patients in outpatient care: A systematic review and meta-analysis.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31581.
    PubMed     Abstract available


  709. BROOCKMAN D, Kalla J, Guerrero A, Budolfson M, et al
    Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31555.
    PubMed     Abstract available


  710. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    PubMed     Abstract available


  711. SARINHO E, Goudouris E, Sole D
    BCG vaccine: Worrying proposal for COVID-19.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31593.
    PubMed     Abstract available


  712. DEGELING C, Williams J, Carter SM, Moss R, et al
    Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Vaccine. 2020 Dec 11. pii: S0264-410X(20)31577.
    PubMed     Abstract available


  713. RASTEGAR M, Tavana M, Meraj A, Mina H, et al
    An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31589.
    PubMed     Abstract available


  714. HOLM MR, Poland GA
    Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31584.
    PubMed    


  715. CARIAS C, Pawaskar M, Nyaku M, Conway JH, et al
    Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US).
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31557.
    PubMed     Abstract available


  716. DHAKAL S, Deshpande S, McMahon M, Strohmeier S, et al
    Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31510.
    PubMed     Abstract available


  717. LENG A, Maitland E, Wang S, Nicholas S, et al
    Individual preferences for COVID-19 vaccination in China.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31576.
    PubMed     Abstract available


  718. GHIGA I, Richardson S, Alvarez AMR, Kato M, et al
    PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31500.
    PubMed     Abstract available


  719. WENZEL NS, Atkins KE, van Leeuwen E, Halloran ME, et al
    Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31282.
    PubMed     Abstract available


  720. MAYKIN MM, Heuser C, Feltovich H
    Pregnant people deserve the protection offered by SARS-CoV-2 vaccines.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31572.
    PubMed    


  721. BOTHUN LS
    COVID-19: The worst date to the senior dance.
    Vaccine. 2020;38:8066-8067.
    PubMed    


    November 2020
  722. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    PubMed     Abstract available


  723. HAVERI A, Ikonen N, Savolainen-Kopra C, Julkunen I, et al
    Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31494.
    PubMed     Abstract available


  724. VANDER STICHELE RH, Hay C, Fladvad M, Sturkenboom MCJM, et al
    How to ensure we can track and trace global use of COVID-19 vaccines?
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31508.
    PubMed    


  725. KITANO T, Aoki H
    A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31506.
    PubMed     Abstract available


  726. URA T, Yamashita A, Mizuki N, Okuda K, et al
    New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31507.
    PubMed     Abstract available


  727. KITTIKRAISAK W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, et al
    Comparison of influenza antibody titers among women who were vaccinated in the 2(nd) and the 3(rd) trimesters of pregnancy.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31472.
    PubMed     Abstract available


  728. DRORI Y, Pando R, Sefty H, Rosenberg A, et al
    Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31394.
    PubMed     Abstract available


  729. GANGULY M, Yeolekar L, Tyagi P, Sagar U, et al
    Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31424.
    PubMed     Abstract available


  730. TUCKERMAN JL, Kaufman J, Danchin M, Marshall HS, et al
    Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions.
    Vaccine. 2020;38:7806-7814.
    PubMed     Abstract available


  731. GARCIA LY, Cerda AA
    Acceptance of a COVID-19 vaccine: A multifactorial consideration.
    Vaccine. 2020;38:7587.
    PubMed    


  732. GRAFFIGNA G, Palamenghi L, Barello S, Stefania B, et al
    "Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.
    Vaccine. 2020;38:7585-7586.
    PubMed    


  733. COUDEVILLE L, Gomez GB, Jollivet O, Harris RC, et al
    Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Vaccine. 2020;38:7588-7595.
    PubMed    


  734. ZHANG W, Gao J, Chen L, Tian J, et al
    Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons.
    Vaccine. 2020 Nov 8. pii: S0264-410X(20)31389.
    PubMed     Abstract available


  735. CHIU SS, Chua H, Kwan MYW, Chan ELY, et al
    Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31401.
    PubMed     Abstract available


  736. SARASTY O, Carpio CE, Hudson D, Guerrero-Ochoa PA, et al
    The demand for a COVID-19 vaccine in Ecuador.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31439.
    PubMed     Abstract available


  737. KESKE S, Mutters NT, Tsioutis C, Ergonul O, et al
    Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31427.
    PubMed     Abstract available


  738. CHEN WH, Tao X, Agrawal AS, Algaissi A, et al
    Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Vaccine. 2020;38:7533-7541.
    PubMed     Abstract available


    October 2020
  739. VESIKARI T, Ramsey K, Pitisuttithum P, Capeding R, et al
    Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31330.
    PubMed     Abstract available


  740. BONANNI P, Angelillo IF, Villani A, Biasci P, et al
    Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic: Appeal from the Board of the Vaccination Calendar for Life in Italy: Maintain and increase coverage also by r
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31318.
    PubMed     Abstract available


  741. CARCELEN AC, Vilajeliu A, Malik F, Gilman RH, et al
    Perceptions and attitudes towards vaccination during pregnancy in a peri urban area of Lima, Peru.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31325.
    PubMed     Abstract available


  742. LIU B, Shi P, Wang T, Zhao Y, et al
    Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31370.
    PubMed     Abstract available


  743. SCHNEIKART G, Tavarini S, Sammicheli C, Torricelli G, et al
    The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31371.
    PubMed     Abstract available


  744. SCHOCH-SPANA M, Brunson EK, Long R, Ruth A, et al
    The public's role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31368.
    PubMed     Abstract available


  745. LIU X, Drelich A, Li W, Chen C, et al
    Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Vaccine. 2020;38:7205-7212.
    PubMed     Abstract available


  746. GUEBRE-XABIER M, Patel N, Tian JH, Zhou B, et al
    NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
    Vaccine. 2020 Oct 23. pii: S0264-410X(20)31373.
    PubMed     Abstract available


  747. CHANDIR S, Siddiqi DA, Mehmood M, Setayesh H, et al
    Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data.
    Vaccine. 2020;38:7146-7155.
    PubMed     Abstract available


  748. RUSCIO BA, Hotez P
    Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response.
    Vaccine. 2020 Oct 21. pii: S0264-410X(20)31364.
    PubMed    


  749. BELL S, Clarke R, Mounier-Jack S, Walker JL, et al
    Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England.
    Vaccine. 2020 Oct 19. pii: S0264-410X(20)31321.
    PubMed     Abstract available


  750. ZHAI Y, Santibanez TA, Kahn KE, Srivastav A, et al
    Rural, urban, and suburban differences in influenza vaccination coverage among children.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31324.
    PubMed     Abstract available


  751. GARCIA PJ, George PE, Romero C, Soto G, et al
    "The flu... is a little more complicated than a cold": Knowledge, beliefs, and practices related to influenza and influenza vaccination among at-risk populations and health professionals in Peru.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31236.
    PubMed     Abstract available


  752. VERGKIZI S, Nikolakakis I
    Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31284.
    PubMed     Abstract available


  753. MALTEZOU HC, Theodoridou K, Tseroni M, Raftopoulos V, et al
    Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January-March 2020.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31276.
    PubMed     Abstract available


  754. MO Y, Zeng J, Xiao C, Zhang, et al
    Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31262.
    PubMed     Abstract available


  755. GOLDMAN RD, Yan TD, Seiler M, Parra Cotanda C, et al
    Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.
    Vaccine. 2020 Oct 10. pii: S0264-410X(20)31317.
    PubMed     Abstract available


  756. SAFAVI A, Kefayat A, Mahdevar E, Abiri A, et al
    Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31307.
    PubMed     Abstract available


  757. RONCATI L, Vadala M, Corazzari V, Palmieri B, et al
    COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31303.
    PubMed     Abstract available


  758. SINGH JA
    COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31302.
    PubMed    


  759. MACIAS AE, McElhaney JE, Chaves SS, Nealon J, et al
    The disease burden of influenza beyond respiratory illness.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31209.
    PubMed     Abstract available


  760. GUILFOYLE K, Major D, Skeldon S, James H, et al
    Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31233.
    PubMed     Abstract available


  761. LEE JKH, Lam GKL, Shin T, Samson SI, et al
    Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31146.
    PubMed     Abstract available


  762. WOLF J, Hansen R, Hassis K, Lapps W, et al
    The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.
    Vaccine. 2020 Oct 5. pii: S0264-410X(20)31228.
    PubMed    


  763. CUSTERS J, Kim D, Leyssen M, Gurwith M, et al
    Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2020 Oct 3. pii: S0264-410X(20)31160.
    PubMed     Abstract available


  764. HOSHI SL, Shono A, Seposo X, Okubo I, et al
    Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
    Vaccine. 2020 Oct 2. pii: S0264-410X(20)31180.
    PubMed     Abstract available


  765. NIANG M, Deming ME, Goudiaby D, Diop OM, et al
    Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31230.
    PubMed     Abstract available


    September 2020
  766. TEMPIA S, Moyes J, Cohen AL, Walaza S, et al
    Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31193.
    PubMed     Abstract available


  767. ANDREW MK, McNeil SA
    Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective.
    Vaccine. 2020 Sep 18. pii: S0264-410X(20)31153.
    PubMed     Abstract available


  768. DETOC M, Bruel S, Frappe P, Tardy B, et al
    Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.
    Vaccine. 2020 Sep 17. pii: S0264-410X(20)31201.
    PubMed     Abstract available


  769. ALHALASEH L, Fayoumi H, Khalil B
    The Health Belief Model in predicting healthcare workers' intention for influenza vaccine uptake in Jordan.
    Vaccine. 2020 Sep 16. pii: S0264-410X(20)31128.
    PubMed     Abstract available


  770. MCMAHON M, Strohmeier S, Rajendran M, Capuano C, et al
    Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice.
    Vaccine. 2020 Sep 15. pii: S0264-410X(20)31119.
    PubMed     Abstract available


  771. DEAN NE, Pastore Y Piontti A, Madewell ZJ, Cummings DAT, et al
    Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
    Vaccine. 2020 Sep 15. pii: S0264-410X(20)31191.
    PubMed     Abstract available


  772. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance.
    Vaccine. 2020 Sep 11. pii: S0264-410X(20)31078.
    PubMed     Abstract available


  773. WANG K, Wong ELY, Ho KF, Cheung AWL, et al
    Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey.
    Vaccine. 2020 Sep 10. pii: S0264-410X(20)31175.
    PubMed     Abstract available


  774. OTIENO NA, Nyawanda B, Otiato F, Adero M, et al
    Knowledge and attitudes towards influenza and influenza vaccination among pregnant women in Kenya.
    Vaccine. 2020 Sep 3. pii: S0264-410X(20)31046.
    PubMed     Abstract available


  775. LAU LHW, Lee SS, Wong NS
    The continuum of influenza vaccine hesitancy among nursing professionals in Hong Kong.
    Vaccine. 2020 Sep 2. pii: S0264-410X(20)31079.
    PubMed     Abstract available


    August 2020
  776. KASE T, Inoue M, Morikawa S, Kumashiro H, et al
    Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
    Vaccine. 2020 Aug 29. pii: S0264-410X(20)31066.
    PubMed     Abstract available


  777. TALAYEV V, Zaichenko I, Svetlova M, Matveichev A, et al
    Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity.
    Vaccine. 2020 Aug 29. pii: S0264-410X(20)30984.
    PubMed     Abstract available


  778. HOWE AS, Pointon L, Gauld N, Paynter J, et al
    Pertussis and influenza immunisation coverage of pregnant women in New Zealand.
    Vaccine. 2020 Aug 28. pii: S0264-410X(20)31071.
    PubMed     Abstract available


  779. AMIN AB, Nunes MC, Tapia MD, Madhi SA, et al
    Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa.
    Vaccine. 2020 Aug 28. pii: S0264-410X(20)30933.
    PubMed     Abstract available


  780. TOMITA Y, Sato R, Ikeda T, Sakagami T, et al
    BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31086.
    PubMed     Abstract available


  781. REITER PL, Pennell ML, Katz ML
    Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31084.
    PubMed     Abstract available


  782. PAGET J, Caini S, Cowling B, Esposito S, et al
    The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31065.
    PubMed    


  783. GALILI U
    Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31073.
    PubMed     Abstract available


  784. ZHOU F, Lindley MC
    Variability in influenza vaccination opportunities and coverage among privately insured children.
    Vaccine. 2020 Aug 18. pii: S0264-410X(20)30992.
    PubMed     Abstract available


  785. HUNG MC, Lu PJ, Srivastav A, Cheng YJ, et al
    Influenza vaccination coverage among adults with diabetes, United States, 2007-08 through 2017-18 seasons.
    Vaccine. 2020 Aug 17. pii: S0264-410X(20)31029.
    PubMed     Abstract available


  786. NEWMAN KL, Stewart LM, Scott EM, Tielsch JM, et al
    Assessment of indirect protection from maternal influenza immunization among non-vaccinated household family members in a randomized controlled trial in Sarlahi, Nepal.
    Vaccine. 2020 Aug 17. pii: S0264-410X(20)31045.
    PubMed     Abstract available


  787. BENNETT N, Crouch S, Hoskins A, Malloy MJ, et al
    'Closing the gap': Evaluating the success of non-mandatory strategies for influenza vaccination of Victorian healthcare workers.
    Vaccine. 2020 Aug 12. pii: S0264-410X(20)31044.
    PubMed     Abstract available


  788. BALASUBRAMANI GK, Choi WS, Nowalk MP, Zimmerman RK, et al
    Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Vaccine. 2020 Aug 12. pii: S0264-410X(20)31032.
    PubMed     Abstract available


  789. GRADY C, Shah S, Miller F, Danis M, et al
    So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development.
    Vaccine. 2020 Aug 11. pii: S0264-410X(20)31048.
    PubMed     Abstract available


  790. KASSIANOS G, MacDonald P, Aloysius I, Reynolds A, et al
    Implementation of the United Kingdom's childhood influenza national vaccination programme: A review of clinical impact and lessons learned over six influenza seasons.
    Vaccine. 2020;38:5747-5758.
    PubMed     Abstract available


  791. FREW PM, Paine MB, Rouphael N, Schamel J, et al
    Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.
    Vaccine. 2020 Aug 10. pii: S0264-410X(20)31006.
    PubMed     Abstract available


  792. YITBAREK K, Abraham G, Girma T, Tilahun T, et al
    The effect of Bacillus Calmette-Guerin (BCG) vaccination in preventing sever infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.
    Vaccine. 2020 Aug 10. pii: S0264-410X(20)31049.
    PubMed     Abstract available


  793. STUURMAN AL, Bollaerts K, Alexandridou M, Biccler J, et al
    Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19.
    Vaccine. 2020 Aug 7. pii: S0264-410X(20)31005.
    PubMed     Abstract available


  794. CHAN MS, Jamieson KH, Albarracin D
    Prospective associations of regional social media messages with attitudes and actual vaccination: A big data and survey study of the influenza vaccine in the United States.
    Vaccine. 2020 Aug 6. pii: S0264-410X(20)30985.
    PubMed     Abstract available


  795. MARELLAPUDI A, King AR, Bednarczyk RA
    Presentation of caregiver-specific vaccine-related information on National Cancer Institute designated cancer center websites.
    Vaccine. 2020 Aug 1. pii: S0264-410X(20)30983.
    PubMed     Abstract available


    July 2020
  796. REN W, Sun H, Gao GF, Chen J, et al
    Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
    Vaccine. 2020;38:5653-5658.
    PubMed     Abstract available


  797. WANG S, Zheng Y, Jin X, Gan Z, et al
    Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)30932.
    PubMed     Abstract available


  798. FORMAN R, Anderson M, Jit M, Mossialos E, et al
    Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)31012.
    PubMed    


  799. KOCHHAR S, Excler JL, Kim D, Robertson JS, et al
    The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)30944.
    PubMed     Abstract available


  800. YEOLEKAR LR, Guilfoyle K, Ganguly M, Tyagi P, et al
    Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30972.
    PubMed     Abstract available


  801. MAZAGATOS C, Godoy P, Munoz Almagro C, Pozo F, et al
    Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017-2019.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30914.
    PubMed     Abstract available


  802. ELLISON TJ, Talbott GC, Henderson DR
    VaxiPatch, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30958.
    PubMed     Abstract available


  803. DIVINO V, Krishnarajah G, Pelton SI, Mould-Quevedo J, et al
    A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30936.
    PubMed     Abstract available


  804. KIM YH, Bang YJ, Park HJ, Li Ko H, et al
    Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30935.
    PubMed     Abstract available


  805. MALTEZOU HC, Theodoridou K, Poland G
    Influenza immunization and COVID-19.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30989.
    PubMed    


  806. KIM HM, Kim DY, Kang YM, Cho HK, et al
    Immunogenicity and protective efficacy of clade 2.3.2.1c and clade 2.3.4.4c H5Nx avian influenza antigen bank vaccines in mice, Korea.
    Vaccine. 2020 Jul 27. pii: S0264-410X(20)30951.
    PubMed    


  807. CHU K, Xu K, Tang R, Tian X, et al
    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged >/=3 years.
    Vaccine. 2020 Jul 27. pii: S0264-410X(20)30872.
    PubMed     Abstract available


  808. VERDIJK P, van der Plas JL, van Brummelen EMJ, Jeeninga RE, et al
    First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial.
    Vaccine. 2020 Jul 25. pii: S0264-410X(20)30947.
    PubMed     Abstract available


  809. KAVIAN N, Hachim A, Poon LLM, Valkenburg SA, et al
    Vaccination with ADCC activating HA peptide epitopes provides 1 partial protection from influenza infection.
    Vaccine. 2020 Jul 24. pii: S0264-410X(20)30908.
    PubMed     Abstract available


  810. WEI J, Li Z, Yang Y, Ma X, et al
    A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy.
    Vaccine. 2020 Jul 23. pii: S0264-410X(20)30915.
    PubMed     Abstract available


  811. LEBRUN-HARRIS LA, Mendel Van Alstyne JA, Sripipatana A
    Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers.
    Vaccine. 2020 Jul 23. pii: S0264-410X(20)30934.
    PubMed     Abstract available


  812. MORO PL, Woo EJ, Marquez P, Cano M, et al
    Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Vaccine. 2020 Jul 21. pii: S0264-410X(20)30907.
    PubMed     Abstract available


  813. SAUNIER F, Berthelot P, Mottet-Auselo B, Pelissier C, et al
    Impact of a decision-aid tool on influenza vaccine coverage among HCW in two French hospitals: A cluster-randomized trial.
    Vaccine. 2020 Jul 16. pii: S0264-410X(20)30911.
    PubMed     Abstract available


  814. SKARLUPKA AL, Handel A, Ross TM
    Influenza hemagglutinin antigenic distance measures capture trends in HAI differences and infection outcomes, but are not suitable predictive tools.
    Vaccine. 2020 Jul 15. pii: S0264-410X(20)30828.
    PubMed     Abstract available


  815. JUNG YJ, Kim KH, Ko EJ, Lee Y, et al
    Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.
    Vaccine. 2020 Jul 13. pii: S0264-410X(20)30878.
    PubMed     Abstract available


  816. HASHEMZADEH A, Avan A, Ferns GA, Khazaei M, et al
    Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
    Vaccine. 2020 Jul 11. pii: S0264-410X(20)30903.
    PubMed     Abstract available


  817. KOCHHAR S, Salmon DA
    Planning for COVID-19 vaccines safety surveillance.
    Vaccine. 2020 Jul 10. pii: S0264-410X(20)30913.
    PubMed    


  818. SU QD, Yi Y, Zou YN, Jia ZY, et al
    The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650.
    Vaccine. 2020;38:5071-5075.
    PubMed     Abstract available


  819. OSAMA EL-GENDY A, Saeed H, Ali AMA, Zawbaa HM, et al
    Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
    Vaccine. 2020 Jul 3. pii: S0264-410X(20)30886.
    PubMed     Abstract available


  820. MELIDOU A, Hungnes O, Pereyaslov D, Adlhoch C, et al
    Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019.
    Vaccine. 2020 Jul 2. pii: S0264-410X(20)30804.
    PubMed     Abstract available


    June 2020
  821. BALZARINI F, Frascella B, Oradini-Alacreu A, Gaetti G, et al
    Does the use of personal electronic health records increase vaccine uptake? A systematic review.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30738.
    PubMed     Abstract available


  822. RAJARAM S, Wojcik R, Moore C, Ortiz de Lejarazu R, et al
    The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30794.
    PubMed     Abstract available


  823. LEE H, Kim HJ, Choe YJ, Shin JY, et al
    Signals and trends of Guillain-Barre syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30824.
    PubMed     Abstract available


  824. PAGUIO JA, Yao JS, Dee EC
    Silver lining of COVID-19: Heightened global interest in pneumococcal and influenza vaccines, an infodemiology study.
    Vaccine. 2020 Jun 25. pii: S0264-410X(20)30855.
    PubMed     Abstract available


  825. GARCIA LY, Cerda AA
    Contingent assessment of the COVID-19 vaccine.
    Vaccine. 2020 Jun 25. pii: S0264-410X(20)30854.
    PubMed     Abstract available


  826. GUIDRY JPD, Coman IA, Vraga EK, O'Donnell NH, et al
    (S)pin the flu vaccine: Recipes for concern.
    Vaccine. 2020 Jun 24. pii: S0264-410X(20)30773.
    PubMed     Abstract available


  827. KARTOGLU UH, Moore KL, Lloyd JS
    Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers.
    Vaccine. 2020 Jun 23. pii: S0264-410X(20)30842.
    PubMed    


  828. HENN W
    Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity.
    Vaccine. 2020 Jun 23. pii: S0264-410X(20)30844.
    PubMed    


  829. BARAL R, Li X, Willem L, Antillon M, et al
    The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30822.
    PubMed     Abstract available


  830. MOEHLING KK, Zimmerman RK, Nowalk MP, Jeng Lin C, et al
    A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.
    Vaccine. 2020 Jun 21. pii: S0264-410X(20)30796.
    PubMed     Abstract available


  831. GRIECO L, Panovska-Griffiths J, van Leeuwen E, Grove P, et al
    Exploring the role of mass immunisation in influenza pandemic preparedness: A modelling study for the UK context.
    Vaccine. 2020 Jun 20. pii: S0264-410X(20)30805.
    PubMed     Abstract available


  832. VAN AALST R, Russo EM, Neupane N, Mahmud SM, et al
    Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable
    Vaccine. 2020 Jun 20. pii: S0264-410X(20)30735.
    PubMed     Abstract available


  833. ULYTE A, Wei W, Gruebner O, Bahler C, et al
    Insights into the protective effects of influenza vaccination: More hospitalizations but lower follow-up mortality during the 2014/15 influenza season in a Swiss cohort.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30791.
    PubMed     Abstract available


  834. MUNOZ FM, Patel SM, Jackson LA, Swamy GK, et al
    Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30704.
    PubMed     Abstract available


  835. THINDWA D, Garcia Quesada M, Liu Y, Bennett J, et al
    Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30833.
    PubMed    


  836. WOLFF GG
    Letter to the Editor.
    Vaccine. 2020;38:4651.
    PubMed    


  837. LAYTON JB, McGrath LJ, Sahrmann JM, Ma Y, et al
    Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.
    Vaccine. 2020 Jun 18. pii: S0264-410X(20)30793.
    PubMed     Abstract available


  838. KELLY MK, Grundmeier RW, Stephens-Shields AJ, Localio R, et al
    Missed opportunities for human papillomavirus vaccination at office visits during which influenza vaccine was administered: An AAP pediatric research in office settings (PROS) national primary care research network study.
    Vaccine. 2020 Jun 12. pii: S0264-410X(20)30757.
    PubMed     Abstract available


  839. COOKENHAM T, Lanzer KG, Gage E, Lorenzo EC, et al
    Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity.
    Vaccine. 2020 Jun 12. pii: S0264-410X(20)30752.
    PubMed     Abstract available


  840. AIDOUD A, Marlet J, Angoulvant D, Debacq C, et al
    Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30725.
    PubMed     Abstract available


  841. PAGLIUSI S, Jarrett S, Hayman B, Kreysa U, et al
    Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30795.
    PubMed     Abstract available


  842. CHOI EJ, Park JH, Chun BC
    Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea.
    Vaccine. 2020 Jun 9. pii: S0264-410X(20)30710.
    PubMed     Abstract available


  843. SCHAEFER GO, Tam CC, Savulescu J, Voo TC, et al
    COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Vaccine. 2020 Jun 4. pii: S0264-410X(20)30768.
    PubMed     Abstract available


  844. MORALES KF, Menning L, Lambach P
    The faces of influenza vaccine recommendation: A Literature review of the determinants and barriers to health providers' recommendation of influenza vaccine in pregnancy.
    Vaccine. 2020 Jun 2. pii: S0264-410X(20)30513.
    PubMed     Abstract available


  845. GLOVER C, Crawford N, Leeb A, Wood N, et al
    Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Vaccine. 2020 Jun 1. pii: S0264-410X(20)30560.
    PubMed     Abstract available


    May 2020
  846. POWELL AM, Luo Z, Martin L, Wan Z, et al
    Corrigendum to "The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals
    Vaccine. 2020 May 27. pii: S0264-410X(20)30673.
    PubMed    


  847. LAMBERT PH, Ambrosino DM, Andersen SR, Baric RS, et al
    Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Vaccine. 2020 May 25. pii: S0264-410X(20)30709.
    PubMed     Abstract available


  848. PAUDEL M, Mahmud S, Buikema A, Korrer S, et al
    Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population.
    Vaccine. 2020 May 20. pii: S0264-410X(20)30638.
    PubMed     Abstract available


  849. PLOTKIN SA, Caplan A
    Extraordinary diseases require extraordinary solutions.
    Vaccine. 2020;38:3987-3988.
    PubMed    


  850. KOPSIDAS I, Tsopela GC, Maroudi-Manta S, Kourkouni E, et al
    Increasing healthcare workers' uptake of seasonal influenza vaccination in a tertiary-care pediatric hospital in Greece with a low-cost, tailor-made, multifaceted strategy.
    Vaccine. 2020 May 16. pii: S0264-410X(20)30639.
    PubMed     Abstract available


  851. ORTA OR, Hatch EE, Regan AK, Perkins R, et al
    A prospective study of influenza vaccination and time to pregnancy.
    Vaccine. 2020 May 11. pii: S0264-410X(20)30548.
    PubMed     Abstract available


  852. MALTEZOU HC, Asimakopoulos G, Stavrou S, Daskalakis G, et al
    Effectiveness of quadrivalent influenza vaccine in pregnant women and infants, 2018-2019.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30564.
    PubMed     Abstract available


  853. WON G, Senevirathne A, Lee JH
    Salmonella Enteritidis ghost vaccine carrying the hemagglutinin globular head (HA1) domain from H1N1 virus protects against salmonellosis and influenza in chickens.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30594.
    PubMed     Abstract available


  854. WRAITH S, Nachbagauer R, Balmaseda A, Stadlbauer D, et al
    Antibody responses to influenza A(H1N1)pdm infection.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30586.
    PubMed     Abstract available


  855. TEMPIA S, Walaza S, Moyes J, McMorrow ML, et al
    Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30539.
    PubMed     Abstract available


  856. LIAO Q, Ng TWY, Cowling BJ
    What influenza vaccination programmes are preferred by healthcare personnel? A discrete choice experiment.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30630.
    PubMed     Abstract available


  857. WAGNER AL, Gordon A, Tallo VL, Simaku A, et al
    Intent to obtain pediatric influenza vaccine among mothers in four middle income countries.
    Vaccine. 2020 May 6. pii: S0264-410X(20)30508.
    PubMed     Abstract available


  858. FRANCIS MJ
    A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
    Vaccine. 2020 May 6. pii: S0264-410X(20)30613.
    PubMed     Abstract available


  859. SMITH LE, Amlot R, Weinman J, Yiend J, et al
    Why do parents not re-vaccinate their child for influenza? A prospective cohort study.
    Vaccine. 2020 May 5. pii: S0264-410X(20)30509.
    PubMed     Abstract available


  860. BELL S, Chantler T, Paterson P, Mounier-Jack S, et al
    Is flu vaccination opt-out feasible? Evidence from vaccination programme implementers and managers in the English National Health Service.
    Vaccine. 2020 May 4. pii: S0264-410X(20)30506.
    PubMed     Abstract available


  861. HAWKSWORTH A, Lockhart R, Crowe J, Maeso R, et al
    Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness.
    Vaccine. 2020 May 3. pii: S0264-410X(20)30462.
    PubMed     Abstract available


    April 2020
  862. NGUYEN VH, Vizzotti C, Uruena A, Giglio N, et al
    Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Vaccine. 2020;38:3682-3689.
    PubMed     Abstract available


  863. HERST CV, Burkholz S, Sidney J, Sette A, et al
    An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.
    Vaccine. 2020 Apr 28. pii: S0264-410X(20)30518.
    PubMed     Abstract available


  864. WANG SH, Chen J, Smith D, Cao Z, et al
    A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus.
    Vaccine. 2020;38:3537-3544.
    PubMed     Abstract available


  865. HOSANGADI D, Warmbrod KL, Martin EK, Adalja A, et al
    Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.
    Vaccine. 2020 Apr 20. pii: S0264-410X(20)30530.
    PubMed    


  866. KAUFMAN J, Attwell K, Tuckerman J, O'Sullivan J, et al
    Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study.
    Vaccine. 2020 Apr 19. pii: S0264-410X(20)30469.
    PubMed     Abstract available


  867. CROSS JW, Joy M, McGee C, Akinyemi O, et al
    Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018).
    Vaccine. 2020 Apr 13. pii: S0264-410X(20)30402.
    PubMed     Abstract available


  868. STAPLETON JT, Wagner N, Tuetken R, Bellamy AR, et al
    High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.
    Vaccine. 2020 Apr 12. pii: S0264-410X(20)30459.
    PubMed     Abstract available


  869. CHANG CY, Cho CY, Lai CC, Lu CY, et al
    Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30437.
    PubMed     Abstract available


  870. SUGISHITA Y, Nakayama T, Sugawara T, Ohkusa Y, et al
    Negative effect on immune response of repeated influenza vaccination and waning effectiveness in interseason for elderly people.
    Vaccine. 2020 Apr 7. pii: S0264-410X(20)30378.
    PubMed     Abstract available


  871. SURAGH TA, Hibbs B, Marquez P, McNeil MM, et al
    Age inappropriate influenza vaccination in infants less than 6 months old, 2010-2018.
    Vaccine. 2020 Apr 6. pii: S0264-410X(20)30418.
    PubMed     Abstract available


    March 2020
  872. AHMED MA, Naus M, Singer J, Valiquette L, et al
    Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13-2016/17, the Canadian Vaccine Safety Network.
    Vaccine. 2020 Mar 27. pii: S0264-410X(20)30371.
    PubMed     Abstract available


  873. O'LEARY ST, Cataldi JR, Lindley MC, Hurley LP, et al
    Impact of media reports regarding influenza vaccine on obstetricians' vaccination practices.
    Vaccine. 2020 Mar 21. pii: S0264-410X(20)30263.
    PubMed     Abstract available


  874. LANE MC, Gordon JL, Jiang C, Leitner WW, et al
    Workshop report: Optimization of animal models to better predict influenza vaccine efficacy.
    Vaccine. 2020;38:2751-2757.
    PubMed     Abstract available


  875. NEUMANN G, Kawaoka Y
    Optimization of animal models to better predict influenza vaccine efficacy (VA).
    Vaccine. 2020;38:2749-2750.
    PubMed    


  876. RUSCIO B, Bolster A, Bresee J
    Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness.
    Vaccine. 2020 Mar 11. pii: S0264-410X(20)30247.
    PubMed     Abstract available


  877. BRAEYE T, Emborg HD, Llorente-Garcia A, Huerta C, et al
    Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project.
    Vaccine. 2020 Mar 11. pii: S0264-410X(20)30326.
    PubMed     Abstract available


  878. CHO HK, Kang YM, Kim HM, Lee CH, et al
    Sales and immunogenicity of commercial vaccines to H9N2 low pathogenic avian influenza virus in Korea from 2007 to 2017.
    Vaccine. 2020 Mar 10. pii: S0264-410X(20)30328.
    PubMed     Abstract available


  879. MOUNIER-JACK S, Bell S, Chantler T, Edwards A, et al
    Organisational factors affecting performance in delivering influenza vaccination to staff in NHS Acute Hospital Trusts in England: A qualitative study.
    Vaccine. 2020 Mar 5. pii: S0264-410X(20)30321.
    PubMed     Abstract available


  880. BELONGIA EA, Levine MZ, Olaiya O, Gross FL, et al
    Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Vaccine. 2020 Mar 4. pii: S0264-410X(20)30278.
    PubMed     Abstract available


  881. DRISCOLL AJ, Arshad SH, Bont L, Brunwasser SM, et al
    Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.
    Vaccine. 2020;38:2435-2448.
    PubMed     Abstract available


    February 2020
  882. POLAND GA
    Another coronavirus, another epidemic, another warning.
    Vaccine. 2020;38:v-vi.
    PubMed    


  883. NABER SK, Bruijning-Verhagen PCJL, de Hoog MLA, van Giessen A, et al
    Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Vaccine. 2020 Feb 27. pii: S0264-410X(20)30084.
    PubMed     Abstract available


  884. KALLIGEROS M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis.
    Vaccine. 2020 Feb 27. pii: S0264-410X(20)30261.
    PubMed     Abstract available


  885. BLYTH CC, Cheng AC, Crawford NW, Clark JE, et al
    The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018.
    Vaccine. 2020 Feb 24. pii: S0264-410X(20)30228.
    PubMed     Abstract available


  886. MUELLER S, Stauft CB, Kalkeri R, Koidei F, et al
    A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.
    Vaccine. 2020 Feb 24. pii: S0264-410X(20)30279.
    PubMed     Abstract available


  887. MOHAMMED H, Roberts CT, Grzeskowiak LE, Giles L, et al
    Psychosocial determinants of pertussis and influenza vaccine uptake in pregnant women: A prospective study.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30217.
    PubMed     Abstract available


  888. HOSCHLER K, Maharjan S, Whitaker H, Southern J, et al
    Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30221.
    PubMed     Abstract available


  889. SAMY N, Reichhardt D, Schmidt D, Chen LM, et al
    Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
    Vaccine. 2020 Feb 11. pii: S0264-410X(20)30081.
    PubMed     Abstract available


  890. FAN J, Cong S, Wang N, Bao H, et al
    Influenza vaccination rate and its association with chronic diseases in China: Results of a national cross-sectional study.
    Vaccine. 2020 Feb 8. pii: S0264-410X(20)30146.
    PubMed     Abstract available


  891. SICCA F, Martinuzzi D, Montomoli E, Huckriede A, et al
    Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement.
    Vaccine. 2020 Feb 7. pii: S0264-410X(20)30141.
    PubMed     Abstract available


  892. PULLAGURA GR, Violette R, Houle SKD, Waite NM, et al
    Shades of gray in vaccination decisions - Understanding community pharmacists' perspectives of, and experiences with, influenza vaccine hesitancy in Ontario, Canada.
    Vaccine. 2020 Feb 6. pii: S0264-410X(20)30137.
    PubMed     Abstract available


  893. VANDERVEN HA, Barr I, Reynaldi A, Wheatley AK, et al
    Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults.
    Vaccine. 2020 Feb 5. pii: S0264-410X(20)30104.
    PubMed     Abstract available


  894. HALES C, Jochems SP, Robinson R, Solorzano C, et al
    Symptoms associated with influenza vaccination and experimental human pneumococcal colonisation of the nasopharynx.
    Vaccine. 2020 Feb 4. pii: S0264-410X(20)30112.
    PubMed     Abstract available


  895. MOURATIDOU E, Lambrou A, Andreopoulou A, Gioula G, et al
    Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019.
    Vaccine. 2020 Feb 4. pii: S0264-410X(20)30135.
    PubMed     Abstract available


  896. BAKER MA, Jankosky C, Yih WK, Gruber S, et al
    The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Vaccine. 2020 Feb 1. pii: S0264-410X(20)30072.
    PubMed     Abstract available


    January 2020
  897. LU Y, Landreth S, Liu G, Brownlie R, et al
    Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.
    Vaccine. 2020 Jan 31. pii: S0264-410X(20)30077.
    PubMed     Abstract available


  898. AKPALU Y, Sullivan SJ, Regan AK
    Association between health insurance coverage and uptake of seasonal influenza vaccine in Brazos County, Texas.
    Vaccine. 2020 Jan 31. pii: S0264-410X(20)30044.
    PubMed     Abstract available


  899. AVALOS LA, Ferber J, Zerbo O, Naleway AL, et al
    Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development.
    Vaccine. 2020 Jan 29. pii: S0264-410X(20)30086.
    PubMed     Abstract available


  900. NGUYEN TTM, Lafond KE, Nguyen TX, Tran PD, et al
    Acceptability of seasonal influenza vaccines among health care workers in Vietnam in 2017.
    Vaccine. 2020 Jan 27. pii: S0264-410X(19)31699.
    PubMed     Abstract available


  901. KING JP, Hanson KE, Donahue JG, Glanz JM, et al
    Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season.
    Vaccine. 2020 Jan 25. pii: S0264-410X(20)30054.
    PubMed     Abstract available


  902. KAZAKOVA A, Kakkola L, Ziegler T, Syrjanen R, et al
    Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods.
    Vaccine. 2020 Jan 24. pii: S0264-410X(20)30037.
    PubMed     Abstract available


  903. LAI E, Tan HY, Kunasekaran M, Chughtai AA, et al
    Influenza vaccine coverage and predictors of vaccination among aged care workers in Sydney Australia.
    Vaccine. 2020 Jan 23. pii: S0264-410X(20)30008.
    PubMed     Abstract available


  904. CASTILLA J, Portillo ME, Casado I, Pozo F, et al
    Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018-2019.
    Vaccine. 2020 Jan 22. pii: S0264-410X(20)30043.
    PubMed     Abstract available


  905. MCDONALD JU, Rigsby P, Atkinson E, Engelhardt OG, et al
    Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study.
    Vaccine. 2020;38:800-807.
    PubMed     Abstract available


  906. CHROMIKOVA V, Tan J, Aslam S, Rajabhathor A, et al
    Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.
    Vaccine. 2020 Jan 17. pii: S0264-410X(20)30012.
    PubMed     Abstract available


  907. MA P, Luo Z, Qian J, Yan Z, et al
    Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.
    Vaccine. 2020 Jan 13. pii: S0264-410X(20)30004.
    PubMed     Abstract available


  908. HUANG C, Fu X, Zhou Y, Mi F, et al
    Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Vaccine. 2020 Jan 13. pii: S0264-410X(19)31625.
    PubMed     Abstract available


  909. XU L, Qin Z, Qiao L, Wen J, et al
    Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates.
    Vaccine. 2020 Jan 11. pii: S0264-410X(19)31718.
    PubMed     Abstract available


  910. JARVIS JR, Dorey RB, Warricker FDM, Alwan NA, et al
    The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: Systematic review and meta-analysis.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31720.
    PubMed     Abstract available


  911. SANDHU SK, Hua W, MaCurdy TE, Franks RL, et al
    Comparison of alpha-spending plans for near real-time monitoring for Guillain-Barre after influenza vaccination during the 2010/11 influenza season.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31674.
    PubMed     Abstract available


  912. RAINISCH G, Adhikari B, Meltzer MI, Langley G, et al
    Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Vaccine. 2020;38:251-257.
    PubMed     Abstract available


    December 2019
  913. LUTZ CS, Fink RV, Cloud AJ, Stevenson J, et al
    Factors associated with perceptions of influenza vaccine safety and effectiveness among adults, United States, 2017-2018.
    Vaccine. 2019 Dec 27. pii: S0264-410X(19)31644.
    PubMed     Abstract available


  914. BEYER WEP, Palache AM, Reperant LA, Boulfich M, et al
    Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines.
    Vaccine. 2019 Dec 23. pii: S0264-410X(19)31679.
    PubMed     Abstract available


  915. GIESE H, Neth H, Moussaid M, Betsch C, et al
    The echo in flu-vaccination echo chambers: Selective attention trumps social influence.
    Vaccine. 2019 Dec 18. pii: S0264-410X(19)31563.
    PubMed     Abstract available


  916. RAO S, Ziniel SI, Khan I, Dempsey A, et al
    Be inFLUential: Evaluation of a multifaceted intervention to increase influenza vaccination rates among pediatric inpatients.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31652.
    PubMed     Abstract available


  917. BERTRAN K, Criado MF, Lee DH, Killmaster L, et al
    Protection of White Leghorn chickens by recombinant fowlpox vector vaccine with an updated H5 insert against Mexican H5N2 avian influenza viruses.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31626.
    PubMed     Abstract available


  918. DHAMAYANTI M, Tarigan R, Fadlyana E, Prasetyo D, et al
    Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31650.
    PubMed     Abstract available


  919. OFFEDDU V, Low MSF, Surendran S, Kembhavi G, et al
    Acceptance and feasibility of school-based seasonal influenza vaccination in Singapore: A qualitative study.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31662.
    PubMed     Abstract available


  920. DE HOOG MLA, Venekamp RP, Meijer A, Sanders EAM, et al
    Inactivated influenza vaccine does not reduce all cause respiratory illness in children with pre-existing medical conditions.
    Vaccine. 2019 Dec 16. pii: S0264-410X(19)31640.
    PubMed     Abstract available


  921. PORTER RM, Goldin S, Lafond KE, Hedman L, et al
    Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic.
    Vaccine. 2019 Dec 12. pii: S0264-410X(19)31548.
    PubMed     Abstract available


  922. GAO Z, Robinson K, Skowronski DM, De Serres G, et al
    Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.
    Vaccine. 2019 Dec 6. pii: S0264-410X(19)31570.
    PubMed     Abstract available


  923. DUONG TN, Thiem VD, Anh DD, Cuong NP, et al
    A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
    Vaccine. 2019 Dec 4. pii: S0264-410X(19)31601.
    PubMed     Abstract available


  924. PAN SC, Hsu WT, Lee WS, Wang NC, et al
    A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(alphaK): A phase II study.
    Vaccine. 2019 Dec 4. pii: S0264-410X(19)31589.
    PubMed     Abstract available


  925. WILSON R, Zaytseva A, Bocquier A, Nokri A, et al
    Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France.
    Vaccine. 2019 Dec 3. pii: S0264-410X(19)31541.
    PubMed     Abstract available


  926. LAMA Y, Hancock GR, Freimuth VS, Jamison AM, et al
    Using classification and regression tree analysis to explore parental influenza vaccine decisions.
    Vaccine. 2019 Dec 2. pii: S0264-410X(19)31568.
    PubMed     Abstract available


    November 2019
  927. MALLORY RM, Nyborg A, Kalyani RN, Yuan Y, et al
    A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
    Vaccine. 2019 Nov 30. pii: S0264-410X(19)31597.
    PubMed     Abstract available


  928. LEE WN, Stuck D, Konty K, Rivers C, et al
    Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial.
    Vaccine. 2019 Nov 29. pii: S0264-410X(19)31595.
    PubMed     Abstract available


  929. JIANG M, Li P, Wang W, Zhao M, et al
    Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31587.
    PubMed     Abstract available


  930. REINDERS S, Romero C, Carcamo C, Tinoco Y, et al
    A community-based survey on influenza and vaccination knowledge, perceptions and practices in Peru.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31539.
    PubMed     Abstract available


  931. PENTA MA, Craciun IC, Baban A
    The power of anticipated regret: Predictors of HPV vaccination and seasonal influenza vaccination acceptability among young Romanians.
    Vaccine. 2019 Nov 27. pii: S0264-410X(19)31571.
    PubMed     Abstract available


  932. HIBBS BF, Ng CS, Museru O, Moro PL, et al
    Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017.
    Vaccine. 2019 Nov 26. pii: S0264-410X(19)31546.
    PubMed     Abstract available


  933. GOSS MD, Temte JL, Barlow S, Temte E, et al
    An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination.
    Vaccine. 2019 Nov 25. pii: S0264-410X(19)31569.
    PubMed     Abstract available


  934. FURER V, Zisman D, Kaufman I, Arad U, et al
    Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.
    Vaccine. 2019 Nov 22. pii: S0264-410X(19)31470.
    PubMed     Abstract available


  935. NOWAK GJ, Evans NJ, Wojdynski BW, Ahn SJG, et al
    Using immersive virtual reality to improve the beliefs and intentions of influenza vaccine avoidant 18-to-49-year-olds: Considerations, effects, and lessons learned.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31516.
    PubMed     Abstract available


  936. WELLIVER RC, Papin JF, Preno A, Ivanov V, et al
    Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31510.
    PubMed     Abstract available


  937. FLOREK K, Mutschler J, McLean HQ, King JP, et al
    Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
    Vaccine. 2019 Nov 18. pii: S0264-410X(19)31440.
    PubMed     Abstract available


  938. PATEL MM, Davis W, Beacham L, Spencer S, et al
    Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31433.
    PubMed     Abstract available


  939. SMATTI MK, Nasrallah GK, Al Thani AA, Yassine HM, et al
    Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31493.
    PubMed     Abstract available


  940. TSUZUKI S, Baguelin M, Pebody R, van Leeuwen E, et al
    Modelling the optimal target age group for seasonal influenza vaccination in Japan.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31508.
    PubMed     Abstract available


  941. NUNEZ IA, Ross TM
    Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses.
    Vaccine. 2019 Nov 13. pii: S0264-410X(19)31497.
    PubMed     Abstract available


  942. KLAUSBERGER M, Leneva IA, Egorov A, Strobl F, et al
    Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections.
    Vaccine. 2019 Nov 9. pii: S0264-410X(19)31472.
    PubMed     Abstract available


  943. TADOUNT F, Doyon-Plourde P, Quach C
    Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review.
    Vaccine. 2019 Nov 8. pii: S0264-410X(19)31480.
    PubMed     Abstract available


  944. HAWKSWORTH A, Jayachander M, Hester S, Mohammed S, et al
    Proteomics as a tool for live attenuated influenza vaccine characterisation.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31471.
    PubMed     Abstract available


  945. KONGCHANAGUL A, Samnuan K, Wirachwong P, Surichan S, et al
    A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31473.
    PubMed     Abstract available


  946. GANCZAK M, Kalinowski P, Drozd-Dabrowska M, Biesiada D, et al
    School life and influenza immunization: A cross-sectional study on vaccination coverage and influencing determinants among Polish teachers.
    Vaccine. 2019 Nov 6. pii: S0264-410X(19)31447.
    PubMed     Abstract available


  947. BROWNE SK, Beeler JA, Roberts JN
    Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naive infants.
    Vaccine. 2019 Nov 6. pii: S0264-410X(19)31428.
    PubMed     Abstract available


  948. MANTEL C, Chu SY, Hyde TB, Lambach P, et al
    Seasonal influenza vaccination in middle-income countries: Assessment of immunization practices in Belarus, Morocco, and Thailand.
    Vaccine. 2019 Nov 4. pii: S0264-410X(19)31401.
    PubMed     Abstract available


  949. CHEN W, Stoecker C
    Mass media coverage and influenza vaccine uptake.
    Vaccine. 2019 Nov 4. pii: S0264-410X(19)31382.
    PubMed     Abstract available


  950. SONG JY, Noh JY, Lee JS, Wie SH, et al
    Effectiveness of repeated influenza vaccination among the elderly population with high annual vaccine uptake rates during the three consecutive A/H3N2 epidemics.
    Vaccine. 2019 Nov 2. pii: S0264-410X(19)31375.
    PubMed     Abstract available


  951. PEBODY RG, Whitaker H, Ellis J, Andrews N, et al
    End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.
    Vaccine. 2019 Nov 1. pii: S0264-410X(19)31460.
    PubMed     Abstract available


    October 2019
  952. OTTEN G, Matassa V, Ciarlet M, Leav B, et al
    A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults>/=65 years of age.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31438.
    PubMed     Abstract available


  953. SHEN AK, Warnock R, Selna W, MaCurdy TE, et al
    Characteristics of vaccinating providers reported through Medicare claims in office-based settings: Volume of influenza and pneumococcal vaccinations.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31402.
    PubMed     Abstract available


  954. STURKENBOOM M, Bahri P, Chiucchiuini A, Grove Krause T, et al
    Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31002.
    PubMed     Abstract available


  955. PALLAS SW, Ahmeti A, Morgan W, Preza I, et al
    Program cost analysis of influenza vaccination of health care workers in Albania.
    Vaccine. 2019 Oct 25. pii: S0264-410X(19)31400.
    PubMed     Abstract available


  956. KANG YM, Cho HK, Kim HM, Lee MH, et al
    Protective efficacy of vaccines of the Korea national antigen bank against the homologous H5Nx clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Vaccine. 2019 Oct 25. pii: S0264-410X(19)31417.
    PubMed     Abstract available


  957. NG TWY, Cowling BJ, So HC, Ip DKM, et al
    Testing an integrative theory of health behavioural change for predicting seasonal influenza vaccination uptake among healthcare workers.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31414.
    PubMed     Abstract available


  958. KOLB EA, Buterbaugh RE, Rinehart CL, Ensley D, et al
    Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31378.
    PubMed     Abstract available


  959. FRAWLEY JE, McManus K, McIntyre E, Seale H, et al
    Uptake of funded influenza vaccines in young Australian children in 2018; parental characteristics, information seeking and attitudes.
    Vaccine. 2019 Oct 23. pii: S0264-410X(19)31406.
    PubMed     Abstract available


  960. PEBODY R, Whitaker H, Zhao H, Andrews N, et al
    Protection provided by influenza vaccine against influenza-related hospitalisation in >/=65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.
    Vaccine. 2019 Oct 22. pii: S0264-410X(19)31405.
    PubMed     Abstract available


  961. PEBODY RG, Zhao H, Whitaker HJ, Ellis J, et al
    Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.
    Vaccine. 2019 Oct 21. pii: S0264-410X(19)31408.
    PubMed     Abstract available


  962. FRIEDMAN L, Renaud A, Hines D, Winter A, et al
    Exploring indirect protection associated with influenza immunization - A systematic review of the literature.
    Vaccine. 2019 Oct 21. pii: S0264-410X(19)31328.
    PubMed     Abstract available


  963. ESSINK B, Fierro C, Rosen J, Figueroa AL, et al
    Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Vaccine. 2019 Oct 18. pii: S0264-410X(19)31384.
    PubMed     Abstract available


  964. MANDON ED, Pizzorno A, Traversier A, Champagne A, et al
    Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.
    Vaccine. 2019 Oct 17. pii: S0264-410X(19)31381.
    PubMed     Abstract available


  965. WOLFF GG
    Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season.
    Vaccine. 2019 Oct 10. pii: S0264-410X(19)31364.
    PubMed     Abstract available


  966. ROBERTS NJ JR
    Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines.
    Vaccine. 2019 Oct 10. pii: S0264-410X(19)31339.
    PubMed     Abstract available


  967. VAN AALST R, Gravenstein S, Mor V, Mahmud SM, et al
    Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
    Vaccine. 2019 Oct 9. pii: S0264-410X(19)31349.
    PubMed     Abstract available


  968. BUFFIN S, Peubez I, Barriere F, Nicolai MC, et al
    Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies.
    Vaccine. 2019 Oct 4. pii: S0264-410X(19)31281.
    PubMed     Abstract available


  969. KOIKE ME, Gattas VL, Lucchesi MBB, Moura de Oliveira MM, et al
    Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan.
    Vaccine. 2019 Oct 4. pii: S0264-410X(19)31324.
    PubMed     Abstract available


    September 2019
  970. BIGGERSTAFF M, Cohen C, Reed C, Tempia S, et al
    A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.
    Vaccine. 2019 Sep 28. pii: S0264-410X(19)31283.
    PubMed     Abstract available


  971. CUTRELL JB, Drechsler H, Bedimo R, Alvarez CA, et al
    Statin use and medically attended acute respiratory illness among influenza vaccine recipients.
    Vaccine. 2019 Sep 19. pii: S0264-410X(19)31224.
    PubMed     Abstract available


  972. GUCLU OA, Demirci H, Ocakoglu G, Guclu Y, et al
    Relationship of pneumococcal and influenza vaccination frequency with health literacy in the rural population in Turkey.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31258.
    PubMed     Abstract available


  973. YITBAREK A, Astill J, Hodgins DC, Parkinson J, et al
    Commensal gut microbiota can modulate adaptive immune responses in chickens vaccinated with whole inactivated avian influenza virus subtype H9N2.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31255.
    PubMed     Abstract available


  974. TEO LM, Smith HE, Lwin MO, Tang WE, et al
    Attitudes and perception of influenza vaccines among older people in Singapore: A qualitative study.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31246.
    PubMed     Abstract available


  975. DONAHUE JG, Kieke BA, King JP, Mascola MA, et al
    Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.
    Vaccine. 2019 Sep 17. pii: S0264-410X(19)31244.
    PubMed     Abstract available


  976. GILES ML, Buttery J, Davey MA, Wallace E, et al
    Pregnant women's knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines.
    Vaccine. 2019 Sep 17. pii: S0264-410X(19)31173.
    PubMed     Abstract available


    August 2019
  977. PATEL N, Massare MJ, Tian JH, Guebre-Xabier M, et al
    Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Vaccine. 2019 Aug 12. pii: S0264-410X(19)31010.
    PubMed     Abstract available


    June 2019
  978. MANARA C, Brazzoli M, Piccioli D, Taccone M, et al
    Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines.
    Vaccine. 2019 Jun 18. pii: S0264-410X(19)30479.
    PubMed     Abstract available


  979. MURALIDHARAN A, Russell MS, Larocque L, Gravel C, et al
    Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice.
    Vaccine. 2019 Jun 8. pii: S0264-410X(19)30753.
    PubMed     Abstract available


    May 2019
  980. O'LEARY ST, Pyrzanowski J, Brewer SE, Sevick C, et al
    Effectiveness of a multimodal intervention to increase vaccination in obstetrics/gynecology settings.
    Vaccine. 2019 May 15. pii: S0264-410X(19)30658.
    PubMed     Abstract available


  981. TORCEL-PAGNON L, Bauchau V, Mahy P, Tin Tin Htar M, et al
    Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe.
    Vaccine. 2019 May 6. pii: S0264-410X(19)30561.
    PubMed     Abstract available


    April 2019
  982. LEROUX-ROELS G, De Boever F, Maes C, Nguyen TL, et al
    Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Vaccine. 2019 Apr 12. pii: S0264-410X(19)30449.
    PubMed     Abstract available


  983. GORMAN DR, Bielecki K, Willocks LJ, Pollock KG, et al
    A qualitative study of vaccination behaviour amongst female Polish migrants in Edinburgh, Scotland.
    Vaccine. 2019 Apr 9. pii: S0264-410X(19)30422.
    PubMed     Abstract available


    February 2019
  984. DOORNEKAMP L, de Jong W, Wagener MN, Goeijenbier M, et al
    Dutch healthcare professionals' opinion on vaccination and education to prevent infections in immunocompromised patients: A mixed-method study with recommendations for daily practice.
    Vaccine. 2019 Feb 7. pii: S0264-410X(19)30160.
    PubMed     Abstract available


    January 2019
  985. QUINN SC, Jamison AM, An J, Hancock GR, et al
    Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake: Results of a national survey of White and African American adults.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30096.
    PubMed     Abstract available


    December 2018
  986. HURLEY LP, Allison MA, Kim L, O'Leary ST, et al
    Primary care physicians' perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults.
    Vaccine. 2018 Dec 28. pii: S0264-410X(18)31704.
    PubMed     Abstract available


    January 2018
  987. VEKEMANS J, Moorthy V, Giersing B, Friede M, et al
    Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.
    Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: